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Heat shock protein 70 (HSP70) takes charge of regulating the level of several oncoproteins 
via folding, disaggregation, and degradation. Since th  level and activity of HSP70 are 
upregulated and hyperactivated in cancer cells compared to normal's, HSP70 belongs to 
potential anti-cancer target. High level of aminoacyl-tRNA synthetase-interacting multi-
functional protein 2-deleted exon 2 (AIMP2-DX2), ano coprotein as well as anti-cancer 
target, accelerates the cancer progression. Since inhibit on of AIMP2-DX2 showed tumor 
regression, studies targeting AIMP2-DX2 have been conducted by using siRNA, shRNA, and 
chemicals. 
 AIMP2-DX2 is increased in cancer cells compared to normal cells through the 
stabilization by HSP70. HSP70 binds to AIMP2-DX2 with two modes of interactions. N-
terminal flexible region of AIMP2-DX2 is recognized by substrate binding pocket in HSP70 
as a substrate and N-terminal GST domain of AIMP2-DX2 interacts with substrate binding 
domain of HSP70 with hydrophobic and electrostatic interactions. Binding of HSP70 on 
AIMP2-DX2 kicks off the access of Siah1, E3 ligase of AIMP2-DX2, and elevates the 
AIMP2-DX2 stability. Increased AIMP2-DX2 by HSP70 promotes AIMP2-DX2-mediated 
cancer progression in vitro and in vivo. Inhibition of the AIMP2-DX2:HSP70 interaction by 
BC-DXI-495, AIMP2-DX2 inhibitor, suppresses the AIMP2-DX2-mediated cancer 
progression. 
 Post-translational modification such as phosphorylation on HSP70 modulates its 
function and affects the cancer cell proliferation. Epidermal growth factor (EGF) 




activated ERK. Phosphorylation of the two sites on HSP70 by ERK changes the 
conformation of HSP70 from un-extended form to extended form which has strong binding 
affinity to client proteins and high folding activity. Enhanced client folding augments the 
level of HSP70 substrates such as Akt and Cdk4, proteins required for cancer cell survival 
and proliferation. Consequentially, phosphorylated HSP70 promotes the cancer cell 
proliferation and progression i vivo. 
 Through the two studies, the regulation of HSP70 function in cancer is revealed. 
Interrupting the interaction of HSP70 with AIMP2-DX2 suppressed stabilization of AIMP2-
DX2 by HSP70, that only influences on the specific substrate, but not others. Phosphorylation 
of HSP70 modulates its folding function and the leve  of cellular proteins, so inhibition of the 
phosphorylation would affect HSP70-dependent cancer. In conclusion, the studies suggest 
AIMP2-DX2:HSP70 interaction and HSP70 phosphorylation as potential targets against 
cancer. 
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Proliferation of cancer cell is accelerated by various high level of oncoproteins compared to 
normal cell. In order to support the cancer cell growth, factors related to protein synthesis and 
quality control are increased especially in cancer cells. Heat shock proteins (HSPs) are 
critical factors to facilitate the production of oncoproteins such as Raf, Akt and Cdk4. HSPs 
implement the role by folding the newly synthesized proteins, refolding the misfolded 
proteins, disaggregating the damaged proteins, and degradation via ubiquitin-mediated 
process. There are several families of HSPs and they are largely categorized according to the 
size of HSPs. HSP90 and HSP70 are well-known HSPs, because those proteins are abundant 
and in charge of central chaperone. HSP90 has been reported as the most important HSP, 
however, the recent studies about HSP70 shed light on the critical role of HSP70 in 
chaperone network. HSP70 has its specific substrate diff rent from HSP90's and is a hub of 
chaperone network, transferring the folded substrates by HSP70 to HSP90 or other HSPs. In 
addition to this, HSP70 solely do the chaperone functio  by itself. Therefore, HSP70 has 
been focused as a potential target against cancer addicted to oncoproteins. Several types of 
the HSP70 inhibitors are developed, retaining the possibility for implication in clinical 
studies. Nevertheless, side effects of HSP70 inhibitor are predicted in reference to the results 
of HSP90 inhibitors from clinical studies. 
 Aminoacyl-tRNA synthetase-interacting multi-functional protein 2-deleted exon 2 
(AIMP2-DX2) is a splicing variant of AIMP2 and their roles are very opposite in cancer cells. 




scaffolding protein of the macromolecular protein complex, AIMP2-DX2 exists as a free 
form in cytoplasm. Since MSC is a central hub of protein translation, AIMP2 influences on 
translation, but also other cellular signaling. Upon the signaling such as UV irradiation, TNF-
α, and TGF-β, AIMP2 is released from the MSC and affects on p53, FBP, and TRAF2 by 
conducting tumor suppressor. In cancer cell lines, AIMP2-DX2 competes with AIMP2 that 
interacts with its partners like p53, FBP, and TRAF2 and consequently results in cancer cell 
proliferation and inhibition of apoptosis. While rarely expressed in normal tissues, AIMP2-
DX2 highly expressed in lung, colon, pancreatic cancer cells and higher level of AIMP2-DX2 
releases drug resistance in vitro and in vivo. Since carcinogen induces the expression of 
AIMP2-DX2 causing carcinogenesis in vivo and higher AIMP2-DX2 in cancer patient tissues 
shows poor prognosis, pathological implication of AIMP2-DX2 is proved. Several studies 
focused on the repressive effect by targeting AIMP2-DX2 using siRNA or inhibitive 
chemicals in cancer progression. Nevertheless, the effective strategy to suppress AIMP2-DX2 
has been veiled and the mechanism of AIMP2-DX2 stabiliz tion has to be disclosed in order 
to inhibit AIMP2-DX2. Here, this study suggests them chanism of AIMP2-DX2 stabilization 
and anti-cancer strategy by targeting the interaction of AIMP2-DX2. 
 HSP70 promotes the cancer progression through augmentation of oncoprotein, 
essential for cell proliferation and anti-apoptosis, caused by increase of its folding. HSP70 
folds its client proteins depending on ATP/ADP binding via chaperone cycle. HSP70 has 3 
domains: nucleotide-binding domain, substrate-binding domain (SBD), and lid which covers 
substrate-binding domain when the client binds. In ATP-binding state, lid binds to nucleotide-
binding domain, that opens the substrate binding pocket in SBD to make easy access of 




function of HSP70 is activated and induces ADP-bound HSP70. ADP-bound HSP70 goes 
through conformation change from lid-docked form to -undocked form, also called as 
extended form. HSP70 in extended form has strong affinity, enough to fold, for the clients. 
Shortly, the folding activity of HSP70 in cellular condition is regulated by the level or ATP-
dependent cycle of HSP70. However, interestingly, it is newly reported that the level of 
HSP70 is not correlated with the amount of folded proteins by HSP70. Moreover, recent 
studies show the importance of modification on HSP70 for its activity. Among the various 
post-translational modification, phosphorylation of HSP70 significantly affects the function 
and disposition of its phosphorylation is distinctive n cancer from normal. Since difference 
of the phosphorylation of HSP70 in cancer from normal would be helpful to use HSP70 as an 
anti-cancer target without side effect in normal tissue, the detailed mechanism of HSP70 
phosphorylation should be unveiled. This report unravels the molecular and cellular effect of 















Tumor-promoting interaction between heat shock protein 70 and AIMP2-
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ERK-dependent phosphorylation on linker and substrate-binding domain 
of HSP70 increases folding activity and cell proliferation 
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AIMP2-DX2: Aminoacyl-tRNA synthetase interacting multif nctional protein 
2-deleted exon 2 
HSP70: Heat Shock Protein 70 
IP: Immunoprecipitation 
EV: Empty vector 
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A tumorigenic factor, AIMP2-DX2, is often up-regulated in many cancers. However, how its 
cellular level is determined is not understood. Here it is reported that HSP70 as a critical 
determinant for AIMP2-DX2 level. The interaction ofthe two factors was identified by 
interactome analysis and structurally determined by x-ray crystallography and NMR analyses. 
HSP70 recognizes the N-terminal flexible region as well as the GST domain of AIMP2-DX2 
via its substrate-binding domain, blocking the Siah1-dependent ubiquitination of AIMP2-
DX2. AIMP2-DX2-induced cell transformation and cancer progression in vivo was further 
augmented by HSP70. Positive correlation between HSP70 and AIMP2-DX2 levels was 
shown in various lung cancer cell lines and patient tissues. Chemical intervention of the 
AIMP2-DX2:HSP70 interaction suppressed cancer cell growth in vitro and in vivo. Thus, this 
work demonstrates the specific tumor-promoting interaction between AIMP2-DX2 and 
HSP70 and its therapeutic potential against cancer. 
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The 70 kDa heat shock proteins (HSP70s) belongs to a family of HSPs1, that play roles in the 
control of protein folding, aggregation, and degradation as well as stress responses2. HSP70 
levels are elevated in response to heat shock or toxins1,3 and are often upregulated in 
cancer4,5.According to the oncogene addiction model, the high demand for protein synthesis 
and folding control in progressed cancers makes them more dependent on HSP706,7, 
prompting investigations into HSP70 as an anti-cancer target4,8.  
HSP70 is composed of the N-terminal ATPase, substrate-binding, and C-terminal lid 
domains9. The ATP or ADP-binding status of the N-terminal domain influences the open and 
close movement of the lid, thereby modulating the affinity of the substrate-binding domain to 
the client protein10.The ATP-bound HSP70 forms an open structure that binds to the substrate, 
which in turn activates hydrolysis of ATP. The ADP-bound HSP70 possesses a high affinity 
for and helps proper folding of the bound protein substrate11. Substrates not successfully 
folded by HSP70 are then transferred to HSP90 and undergo an additional folding process12,13. 
It was recently reported that HSP70 can prevent the bound substrates from ubiquitin-
dependent degradation by disaggregation although the detailed working mechanism remains 
unclear14. 
Aminoacyl-tRNA synthetase-interacting multi-functional protein 2 (AIMP2) serves 
as a scaffold in the assembly of the multi-tRNA synthetase complex (MSC), macromolecular 
protein complex15,16. AIMP2 dissociation from the MSC influences the activity of the p53, 




a splicing variant of AIMP2 lacking exon 2, AIMP2-DX2 (DX2 hereafter), that is generated 
by alternative splicing positively correlates with the aggressiveness of cancer. 
DX2compromises the tumor suppressive function of the native AIMP2 (AIMP2-F hereafter) 
through competitive interactions with p53, FBP, and TRAF222,23. While rarely expressed in 
normal tissues, DX2 is highly expressed in lung, pancreatic and colon cancer tissues22,24 and 
can be induced by a chemical carcinogen to promote cancer progression22. Increased levels of 
DX2 have been observed in chemo-resistant ovarian cancer cells23 and its levels positively 
correlate with cancer stage and patient lethality22,24. Specific suppression ofDX2 expression 
with its specific siRNA or chemicals was shown to reduce tumor growth, suggesting its 
potential efficacy as therapeutic target22,23,25,26. Despite its significance as a potential marker 
and therapeutic target against cancer, the factor and mechanism to determine the cellular level 
of DX2 are not known yet. Here, this study shows that HSP70 specifically recognizes and 
stabilizes DX2 and demonstrate a mechanism for this activity. It is also validated the 













The interaction of DX2 with HSP70 
To understand the mechanisms by which cells augment the levels of DX2 protein, DX2-
interacting cellular factors are identified by affinity purification using immobilized 
streptavidin (strep)-tagged DX2, followed by liquid chromatography-mass spectrometry (LC-
MS) (Fig. 1a). 107 proteins were identified as potential DX2 interactors (Fig. 1b-c, and Table 
1), and ontological classification revealed that HSP70 family proteins were predominant 
among the top 50 interactors. These included HSPA8, HSPA5, HSPA9, HSPA2, HSPA1L, 
HSPA4, and HSPA1A (Fig. 1d).  
To determine whether the interaction of DX2 with HSP70 is direct and specific, I 
performed an in vitro pull-down assay using purified GST-DX2 in cell lysates expressing 
GFP-HSP70 or -HSP90. As shown in Fig. 2a, DX2 bound to HSP70, but not to HSP90. I also 
showed the endogenous interaction of HSP70 and DX2 by co-immunoprecipitation using 
specific antibodies against DX2 and HSP70 (Fig. 2b). The domains responsible for the 
interaction were determined by repeating the co-immunoprecipitation experiments using 
truncated versions of DX2 and HSP70 containing different domains. HSP70 consists of a 
nucleotide-binding domain (NBD, 1-384 aa), substrate-binding domain (SBD, 385-536 aa) 
and Lid (537-641 aa)9, while DX2 contains an N-terminal flexible region (NFR, 1-50 aa), 
GST-N-terminal domain (51-151 aa), and GST-C-terminal domain (152-251 aa) (Fig. 2e)22. 
Using different combinations of these domains in i  vitro pull-down assay and 




interacted withHSP70’s SBD (Fig. 2c-e). 
 
Roles of HSP70 in stabilization and oncogenicity of DX2 
To gain insight into the functional importance of the HSP70-DX2 interaction, I monitored the 
level of DX2 in cells which HSP70 was either overexpressed or downregulated by siRNA. It 
was observed that a positive dependence of the DX2 protein, but not its mRNA, on HSP70 
expression, suggesting that HSP70 plays a role in modulating DX2 abundance at the post-
transcriptional level (Fig. 3a). To determine the eff ct of HSP70 on cellular turnover of DX2, 
nanoluciferase-tagged DX2 was expressed in HSP70 up- and down-regulated 293T cells that 
were treated with cycloheximide to block de novo protein synthesis. The cellular stability of 
DX2 was significantly extended by the overexpression of HSP70 while reduced by the 
suppression of HSP70 (Fig. 3b). Then, it was examined whether levels of HSP70 affected the 
ubiquitination of DX2 by monitoring the ubiquitinated-DX2 using an HA-tagged ubiquitin 
(ub) and immunoblotting with HA antibody. As shown in Fig. 3c, high levels of HSP70 
reduced the ubiquitination of DX2. To see whether the effect of HSP70 on DX2 stability I 
observed in cell culture extends more broadly, I determined the cellular levels of HSP70 and 
DX2 in various human lung normal and cancer cell lines by Western blot analysis. Out of the 
29 tested cell lines, 21 showed that expression levels of the two proteins positively correlated 
(Fig. 3d-e). Using four cell lines in which endogenous DX2 levels are intrinsically low, I 
tested whether ectopic expression of HSP70 increases the endogenous DX2 expression. As 
shown in Fig. 3f, HSP70 enhanced DX2 levels in dose-dependent manner. 
The relationship between HSP70 and DX2 was tested by measuring their levels in 




Among the 112 tissues tested, 73% showed a positive corr lation between HSP70 and DX2 
expression (Fig. 4b and 4d left). To further confirm this observation, levels of the two 
proteins were compared in tumor and matched normal (MN) tissues from same patients. Of 
the tissues from the 75 patients tested, 27 showed a simultaneous, tumor-specific increase in 
the levels of both proteins (Fig. 4c and 4d right). Together, these results suggest that HSP70 
plays a significant role in controlling DX2 stability with pathological implications when the 
two factors are present in tumors. 
To assess the tumorigenicity of the two factors, I monitored the combined effects of 
HSP70 and DX2 levels on cell viability. Strep-DX2 was introduced into 293T cells which is 
expressed with siRNA against HSP70, and cell viability was determined by colorimetric 
assay. Ectopic expression of DX2 resulted in enhanced cell viability whereas suppression of 
HSP70 expression resulted in decreased cell viability (Fig. 5a-b). To validate these results, I 
conducted an analogous experiment using the construct  in a DX2-inducible A549 stable cell 
line. A549 cells were transfected with construct expr ssing DX2 under control of an inducible 
promoter (Strep-DX2) and empty vector control (Strep-EV) and si-RNA against HSP70, 
treated with doxycycline to induce DX2, and cell viability was determined. When DX2 was 
induced by the treatment of doxycycline, cell viability was increased significantly (Fig. 4c, 
red). However, this effect was reduced in cells which HSP70 expression was suppressed (Fig. 
4c, blue). Then, it was evaluated that the relationship between HSP70 and DX2 in cell 
transformation using an anchorage-independent colony f rmation assay, using the same 
strategy but with a sh-HSP70 construct to suppress HSP70 expression. Cells expressing both 
Strep-DX2 and HSP70 yielded the highest number of colonies while cells expressing Strep-




augments the tumorigenicty of DX2. 
 
Structural analysis of the DX2 and HSP70 interaction 
The data above in Figure 1 showed the significance of DX2’s NFR (DX2-NFR) for its 
interaction with HSP70. The substrate-binding pocket of HSP70’s substrate-binding domain 
(HSP70-SBD) is known to preferentially accept flexible peptides containing hydrophobic 
amino acids27. Since DX2-NFR harbors several hydrophobic residues (Fig. 6a), It was 
determined whether DX2-NFR could bind to HSP70-SBD by performing a competition assay 
between DX2 and NRLLLTG, a well-known substrate sequence corresponding to the 
substrate binding pocket of HSP70-SBD, and monitoring the binding of DX2-NFR to HSP70 
by NMR analysis*. The NMR signals detected theDX2-NFR shifted upon HSP70 binding 
(Fig. 6b, red) and shifted back upon the addition of NRLLLTG peptide (Fig. 6b, green), 
implying that DX2-NFRbound to the substrate-binding pocket of HSP70-SBD. 
The binding region of DX2-NFR was next determined by measuring heteronuclear 
nuclear Over hauser effects (NOE), which indicated that the amide signals of DX2-NFR with 
the restricted motions were presented in an HSP70-bound state. When in the HSP70-bound 
state, the DX2-NFR residues ranging from Y25 to R33 showed positive values for the 
heteronuclear NOEs, whereas in the free state, the same residues showed negative values, 
indicating that the HSP70 binding enhanced the rigidity of those residues (Fig. 6c, upper). 
The amide signals of those residues also showed large chemical shift perturbation (CSP) 
                                           
* NMR analysis, crystallization, and modeling of protein structure were supported from professor 




values when in the bound state (Fig. 6c bottom, and 6d). To further validate these results, I 
determined the region of DX2-NFR responsible for its interaction with HSP70 using a co-
immunoprecipitation assay and observed that DX224-34 (the peptide from M24 to S34 of DX2) 
showed the strongest binding to HSP70 (Fig. 6e), consistent to the results of the heteronuclear 
NOE measurement. Taken together, these data indicate  that the region of DX2-NFR 
spanning residues M24 to R33 is critical for its access to the substrate-binding pocket of 
HSP70. 
Next the X-ray crystal structure of the DX2-NFR-deriv d peptide, 
24MYRLPNVHG32, complexed with HSP70-SBD was determined. Crystals from a fusion 
protein denoting HSP70395-537-MYRLPNVHG, comprised of HSP70-SBD and the DX2 peptide 
were obtained (Fig. 7a). The protein was crystallized in a space group P212121 with two 
molecules in the asymmetric unit. The structure wasrefined at 1.79Å resolution to Rwork and 
Rfree values of 0.18 and 0.22, respectively (Fig. 7b).The structure revealed that the T429, 
A406 and L439 residues of HSP70 form hydrogen bonds with Y25 and L27, R26, and P28 of 
DX2, respectively. In addition, the L27 residue of DX2 binds to a hydrophobic pocket formed 
by the L403, F428, V438, and I440 residues of HSP70. The L27 position of DX2 is 
designated S0 in the sequence of substrate bound to HSP7028 (Fig. 7c). The bound structure 
of MYRLPNVHG in HSP70 was strikingly similar to the pyrrhocoricin-derived peptide, LY 
Cha LPRPT, of DnaK (PDB 3DPP)29 (Fig. 7d), showing that the mode of binding may be 
similar in the two cases. 
Based on the information from crystal structure, I substituted hydrophobic residues in 
DX2 with alanine and conducted further binding assay . Among the four mutants of DX224-




HSP70 binding (Fig. 7e), suggesting the importance of these residues for the interaction of 
DX2 with HSP70. In HSP70, substituting alanine for F428, a residue known to be critical for 
substrate binding30, also reduced the interaction between HSP70 and DX224-34 (Fig. 7f). The 
binding of DX224-34to HSP70 was reduced by the addition of the “NRLLLTG” peptide in a 
dose-dependent manner, suggesting that DX2-NFR accesses the substrate-binding pocket of 
HSP70-SBD (Fig. 7g). Taken together, these results indicate that HSP70 recognizes DX2 
through its typical substrate-binding mode. 
Deletion mapping suggested that DX2 makes an additional interaction with HSP70 
via its GST domain (Fig. 2e). To uncover the exact mode f binding between DX2-GST and 
HSP70-SBD, the residues of each protein responsible for this interaction were determined 
using NMR-based chemical-shift-perturbation (CSP) analysis. The CSP analysis using 15N-
labelled DX251-251 suggested that upon binding the HSP70, several residu  on the surface of 
the β-sheet in DX2-GST were perturbed (Fig. 8b and c), and that four hydrophobic and four 
positively charged residues are proposed to be critical for the interaction with HSP70. These 
eight DX2 residues were then mutated and co-immunopreci itation experiments were 
performed to confirm their importance for binding to HSP70 (Fig. 8d). This analysis 
indicated that the L97 and T117residues in the hydrophobic pocket and the K125 and K129 
residues on the positively-charged electrostatic surface of DX2-GST were required for 
HSP70 binding (Fig. 8a and 8e-g). A further CSP analysis using 15N-labelled HSP70386-543 
uncovered the perturbation of the residues located near the hinge region between the α-helical 
Lid and β-stranded SBD domains (Fig. 9b and c). Since several r sidues in hydrophobic and 
negatively-charged electrostatic surface were suggested to be critical for the interaction with 




immunoprecipitation assay (Fig. 9d). These results suggested that the L486 and I503 in the 
hydrophobic pocket and the D395 and D481 residues on the negative-charged electrostatic 
surface are critical for HSP70 binding to DX2 (Fig. 9a and 9e-g). Interestingly, the binding 
surfaces of the DX2-GST and HSP70-SBD domains show charge-complementarities in 
which the surfaces of DX2 and HSP70 are highly positive and negative (Fig. 8a and 9a), 
respectively, which is reminiscent of the typical sub trate-binding mode of HSPs31. 
Next I investigated the significance of HSP70 for stabilization and tumor-promoting 
function of DX2 using the binding-defective mutants of both proteins. In contrast to DX2 
wild type (WT), whose levels increased upon introduction of HSP70, the levels of the 
HSP70-binding defective DX2 mutants such as T117A, K125A and L27A remained 
unchanged (Fig. 10a, left). Conversely, all of the HSP70 mutants defective in binding to DX2, 
such as L486A, D395A and F428A, also failed to increase the levels of DX2 (Fig. 10a, right). 
Moreover, a cell viability assay showed that unlike wild type (WT), the HSP70-binding 
defective DX2 mutants, T117A, K125A and L27A, failed to enhance 293T cell viability (Fig. 
10b). 
Based on information from the binding studies using NMR, x-ray crystallography 
and site-directed mutagenesis, a model for the complex of DX2 and HSP70 SBD395-537 was 
generated (Fig. 10c). This model shows the hydrophobic interaction of DX2-NFR in the 
substrate-binding pocket of HSP70-SBD, and the hydrophobic and electrostatic interactions 
of DX2-GST with the hinge region between alpha-helical Lid and beta-stranded SBD. The 
interactions occurring at the two separated regions of HSP70 may cooperatively facilitate the 





Inhibitory effect of HSP70 on Siah1-mediated degradation of DX2 
I then investigated the detailed mechanism by which HSP70 inhibits the ubiquitination of 
DX2. Siah1 was previously reported to be an E3 ligase that delivers ubiquitin to DX232. I 
confirmed this previous observation by checking the int raction of endogenous Siah1 and 
DX2 by mutual co-immunoprecipitation in 293T cells (Fig. 11a). Then, it was tested whether 
HSP70 affects the binding of Siah1 to DX2 using co-immunoprecipitation and in vitro pull-
down assays in 293T cells expressing Strep-DX2, FLAG-Siah1 and GFP-HSP70, and co-
precipitated Siah1 and HSP70 with DX2 were analyzed. As shown in Fig. 10b, the binding of 
Siah1 to DX2 was suppressed by ectopic expression of HSP70 (Fig. 10b). Direct binding of 
the two proteins was also reduced by an increase in HSP70, as shown by a pull-down assay in 
which purified GST-DX2 was mixed with the cell lysates expressing FLAG-Siah1 and 
different levels of GFP-HSP70 (Fig. 10c). These results suggest that HSP70 could 
competitively block the binding of Siah1 to DX2.The DX2 level was decreased by ectopic 
expression of Siah1and restored by HSP70 (Fig. 10d), confirming that HSP70 and Siah1 have 
a functional relationship in the control of DX2 level.  
To determine the interaction regions of Siah1 and DX2, I performed co-
immunoprecipitation using the separate domains of the two proteins. The substrate-binding 
domain (SBD) of Siah1 showed to bind to the same NFR and GST-N domain of DX2 (Fig. 
10e and f) responsible for binding to HSP70 (Fig. 10g). To confirm whether HSP70 binding 
is critical for blocking Siah1-mediated ubiquitination of DX2, I induced DX2 ubiquitination 
by ectopic expression of Siah1 and compared the effect of HSP70 WT and DX2-binding-
defective F428A mutant on DX2 ubiquitination. As shown in Fig. 10h, Siah1-dependent 




data suggest that HSP70 competitively inhibits Siah1 binding to and ubiquitination of DX2, 
resulting in an increase in DX2 levels. 
 
Chemical inhibition of HSP70-DX2 interaction  
The data above shows that HSP70 augments the oncogeni  activity of DX2 and expression of 
the two proteins are positively correlated in many cancer cells. To determine the therapeutic 
potential of blocking the interaction between DX2 and HSP70, a chemical screen was 
conducted to identify inhibitors that can reduce th cellular stability of DX2 as a consequence 
of disrupting its interaction with HSP70. A549 cells expressing nanoluciferase-tagged DX2 
were treated with 100 chemicals† that were derived from the BC-DXI-04, which has 
previously revealed to decrease the level of DX225. The effect of the chemicals on the 
nanoluciferase-DX2 stability was determined by monitoring its luminescence (Fig. 12a). 34 
chemicals were selected that reduced the luminescence signal by more than 40 % compared 
to the untreated control. These chemicals were subjected to a secondary screening to 
determine their effect on the AIMP2-F level and cell viability in lung cancer and normal cells 
(Fig. 12b). One of the chemicals, BC-DXI-495, was finally selected as a hit compound (Fig. 
12c). BC-DXI-495 specifically reduced the levels of DX2 (IC50: 4.2 μM), but not AIMP2-F, 
and reduced the viability of lung cancer cells (EC50: 14 μM), but not normal cells (Fig. 12d). 
Moreover, in H460 cells, BC-DXI-495 specifically reduced the levels of endogenous DX2 
protein, not mRNA (Fig. 12e).  
                                           
† 100 chemicals are derivatives of BC-DXI-04 and all the chemicals were synthesized from 




To confirm BC-DXI-495’s specific inhibition of the DX2-HSP70 interaction in cells, 
Strep-DX2-expressing cell lysates in the presence ad absence of the chemical were reacted 
with Strep-tactin column. Co-precipitated proteins were separated by SDS-PAGE (Fig. 13a, 
left). In the cell lysate without BC-DXI-495, a major protein band was detected that co-
precipitated with Strep-DX2. This band was eliminated in the chemical-treated lysate (Fig. 
13a, right). Isolation of the protein band and LC-MS analysis revealed that the protein was 
HSP70. These results suggest that the interaction of DX2 with HSP70 was specifically 
inhibited by BC-DXI-495. I then performed an enzyme-linked immunosorbent assay (ELISA) 
by adding different amounts of BC-DXI-495 to the DX2 and HSP70 pair to test for its ability 
to directly inhibit the binding of two proteins. The addition of BC-DXI-495 reduced the 
interaction of the two proteins in a dose-dependent manner (Fig. 13b). I also performed 
Siah1-mediated ubiquitination of DX2 to determine whether BC-DXI-495 affects this process. 
As shown in Fig. 13c, increasing amounts of the chemical gradually enhanced the Siah1-
mediatedubiquitination of DX2, which was blocked by HSP70. Together, the data suggests 
that BC-DXI-495 inhibits the interaction between DX2 and HSP70 and increase the 
ubiquitination-dependent turnover of DX2. 
 
The effect of BC-DXI-495 on DX2-dependent cancer progression 
Since BC-DXI-495 stimulates DX2 degradation by inhibiting HSP70 binding to DX2, I 
tested whether it also affects DX2-dependent cell growth in a DX2-inducible cell line. The 
data indicated that induction of DX2 significantly enhanced cell viability and BC-DXI-495 
efficiently diminished DX2 activity (Fig. 14a, pink lines). However, the effect of the chemical 




measured the changes in DX2 levels after treating the same cells with BC-DXI-495 and 
observed that the levels of DX2 induced by the doxycycline treatment was decreased by the 
treatment of BC-DXI-495 (Fig. 14b). I then estimated the EC50 of BC-DXI-495 in lung cell 
lines expressing different levels of DX2 and observed that the cell lines with higher amounts 
of DX2 were more sensitive to the cytotoxicity of BC-DXI-495 (Fig. 14c). The effect of BC-
DXI-495 on cancer progression i  vivo was then further evaluated using a xenograft model f 
H460 cells. Tumor growth was significantly diminished by the administration of BC-DXI-
495 with little effect on body weight (Fig. 14d-g). I also determined the endogenous levels of 
DX2 and HSP70 in isolated tumors and observed a specific decline in DX2 which indicated 
that BC-DXI-495 exerted a specific suppressive effect on DX2 levels (Fig. 14h). 
 
Determination of the chemical binding surface in DX2 
To understand the mode of action of BC-DXI-495, BC-DXI-495 was biotinylated at several 
positions (Biotin-495) and compared the effects on DX2 levels in H460 cells. Among the four 
biotinylated derivatives, biotin-495-#1 was selected for further experiments since it showed 
most potent suppression of DX2 levels (Fig. 15a). To identify the target of BC-DXI-495, I 
reacted biotin-495 either with GFP-DX2 or GFP-HSP70, co-precipitated the complex, and 
analyzed them by Western blot analysis. As shown in Fig. 15b, the precipitate contained GFP-
DX2 but not GFP-HSP70. To further confirm the specific binding of BC-DXI-495 to DX2, I 
performed competitive binding assay of BC-DXI-495 and biotin-495 to DX2. The amount of 
DX2 that co-precipitated with Biotin-495 was significantly decreased in the group pre-treated 
with BC-DXI-495 (Fig. 15c). 




resonance (SPR) assay and the results indicate that BC-DXI-495 binds to DX2 with a KD of 
approximately 14 μM (Fig. 15d), which is similar to the IC50 value for its suppression of DX2 
levels (Fig. 12d). Then, the BC-DXI-495 binding region of DX2 was determined using a 
NMR-based chemical shift perturbation (CSP) assay. Several residues of DX2 were perturbed 
by adding BC-DXI-495 (Fig. 16a-b) that suggested a hydrophobic pocket on surface of DX2 
as a candidate chemical binding region. To identify the residues responsible for binding, I 
introduced alanine substitutions at potentially important residues and determined the effect on 
the HSP70-DX2 interaction. The alanine substitution at the L80, T82, F116, T117 and K129 
residues ablated the effect of BC-DXI-495 (Fig. 16c), suggesting they engage in binding to 
the chemical. Based on these results, a structural modeling study was performed in which 
BC-DXI-495 was docked into the hydrophobic pocket of DX2 surrounding L80, T82, F116 
and T117 residues (Fig. 16d). This hydrophobic pocket is proximal to the binding surface for 
HSP70, suggesting that binding of BC-DXI-495 to DX2 could interfere with the binding of 
HSP70 (Fig. 16e). Prompted by our data showing that BC-DXI-495 specifically inhibited the 
interaction of HSP70 with DX2, I tested its effect on DX2-induced tumor growth in vivo by 
intraperitoneally administering the chemical into mice embedded with H460 cells stably 
expressing either DX2 wild type (WT) or the DX2 L80A mutant that does not bind the 
chemical. BC-DXI-495 significantly suppressed the growth and weight of tumors expressing 
DX2 WT and not those expressing the L80A mutant (Fig. 17a-c), while not affecting body 
weights of the tested mice (Fig. 17d). In addition, the level of DX2 WT was significantly 
reduced whereas the level of the L80A mutant was unaffected in the chemical-treated tumors 
(Fig. 17e). Taken together, the results indicate that BC-DXI-495 exerts its tumor suppressive 










Figure 1. a, Strategy for interactome analysis of DX2. Proteins co-precipitated with Strep-
tagged DX2 were identified by LC-MS analysis. Empty vector (EV) was used as a negative 
control for DX2. b, Ontology classification of proteins that interacted with DX2. c, Ontology 
classification of proteins interacted with DX2. The symbols of the interacting proteins are 
indicated in the ovals. Most of DX2-interacting proteins involved in protein folding are 
isoforms of the HSP70 family. d, Relative abundance of top 50 proteins specifically 
identified as binding proteins of DX2 from interactome analysis. Identified isoforms of 
















Figure 2. Specific binding of DX2 and HSP70 through its 1-151 amino acids and 





Figure 2.  a, In vitro pull-down showing specific interaction of DX2 with HSP70. GST-DX2 
protein was incubated with cell lysates expressing GFP-HSP70 or -HSP90 and precipitated 
with glutathione-Sepharose beads. Co-precipitates wre subjected to SDS-PAGE and 
immunoblotting using specific antibody against GFP. The amounts of GST proteins were 
determined by Coomassie staining. Arrows denotes the GST proteins. b, Endogenous 
immunoprecipitation showing the binding between DX2 and HSP70. Endogenous DX2 and 
HSP70 were precipitated with their specific antibodies in left and right panel experiment, 
respectively. c-e, Determination of peptide regions responsible for binding of DX2 and 
HSP70. (c) GST-HSP70 was incubated with the cell lysates containing the full length GFP-
tagged DX2 (Full) and three GFP-tagged DX2 fragments: NFR, GST and GST-C. HSP70 co-
precipitated were subjected to SDS-PAGE and immunoblotting with the antibody against 
GFP was used to detect GFP fusion or full length DX2 and its fragments, and coomassie 
staining to detect GST. (d) Each of version of GFP-, either fused to full-length HSP70 
(Full)or its NBD, SBD, and Lid domains, was introduced into 293T cells expressing Strep-
DX2. DX2 was precipitated using a Strep-tactin column and the co-precipitated HSP70 
domain was detected by Western blotting using a specific antibody against GFP. e, Schematic 
diagram showing the interaction between DX2 and HSP70. Peptide regions involved in the 
interaction of two proteins are depicted as a dashed lin . NFR, N-terminal flexible region; 








Figure 3. Significance of HSP70 for stabilization of DX2.  
 




GFP-HSP70 or a specific si-RNA against HSP70, respectively. Protein and mRNA levels of 
DX2 in these cells were detected by Western blotting (WB) and RT-PCR (RT), respectively. 
Actin was used as a loading control. b, Protein stability of nanoluciferase-tagged-DX2 was 
evaluated at time intervals after cycloheximide (CHX) treatment using a luciferase assay. 
HSP70 expression was modulated as described above in Fig. 2a. c, HSP70-dependent control 
of DX2 ubiquitination. HSP70 was overexpressed or suppressed by the introduction of GFP-
HSP70 or si-HSP70, respectively, in 293T cells exprssing Strep-DX2 and HA-ub. Amounts 
of ubiquitinated DX2 were determined by immunoblotting with an anti-HA antibody. d, 
Levels of DX2 and HSP70 in various lung cell lines including cancer and normal were 
analyzed by Western blotting. Relative levels of both proteins in different cell lines were 
measured and presented in the graph. A dotted line shows the relationship between the 
expression of DX2 and HSP70. X and Y axis denotes th  relative level of DX2 and HSP70. e, 
Levels of DX2 and HSP70 in 29 cancer and normal lung cell lines were determined by 
immunoblotting using their specific antibodies. Protein levels were normalized using actin as 
a loading control. The normalized levels were graded from 0 to 10 and visualized as blue and 
red for DX2 and HSP70, respectively. Cell lines were a ranged according to their grade of 
DX2 level. e, Increasing amounts of GFP-HSP70 were introduced into four different cells 
expressing low levels of endogenous DX2 and HSP70, and the level of DX2, GFP, and actin 








Figure 4. Analysis of DX2 and HSP70 expression in lung cancer patient tissue.  
 
Figure 4. a-c, (a) Tissue micro array including lung cancer and matched normal tissues was 
subjected to immunohistochemistry (IHC) staining with anti-DX2 and -HSP70 antibodies. 
The staining levels were graded from 0 to 2 (for DX2, 0 is low and 1 and 2 are high; for 




and NC denote low, high and not changed, respectively. d-e, Analyzed results in the tissues 
from cancer patients (lung tumor; d) and cancer compared to matched normal (MN) from 
same patients (lung tumor/MN; e) are presented as pi charts with the number of analyzed 



















Figure 5. Effect of HSP70 on DX2-mediated proliferation.  
 
Figure 5..a-b, (a) Cell viability of 293T cells expressing the indicated combination of si-
HSP70 and Strep-DX2 was measured by MTT assay. Empty vector (EV) and si-control (si-
con) were used as a negative control. The values of the cell viability relative to that of the 
cells expressing EV and si-control are shown as a bar graph. (b) The same cells as described 
above were subjected to EdU staining to determine lev ls of DNA synthesis. DAPI was used 
for staining of nuclei and normalization. c, Strep-EV- or Strep-DX2-inducible A549 cells 
(ind-EV and ind-DX2, respectively) were transfected with si-RNA against HSP70 or control 
siRNA (si-con and si-HSP70, respectively) and treated with doxycycline to induce DX2 
expression. Cell viability was determined at time intervals by MTT assay. d, H460 cells 




independent colony formation assay. The colony number from each cell line was presented as 
a bar graph (left) with representative images of processed cells shown (right). All the 




















Figure 6. Evaluation of DX2 region significant for its binding to the substrate-binding 
pocket of HSP70.  
 
Figure 6. a, Sequence of N-terminal flexible region (NFR). Hydrophobic amino acids are 




TROSY spectra of 15N-labeled DX21-251 (black contours) in the presence of HSP701-641 (red), 
or in the presence of both HSP701-641 and NRLLLTG peptide (green). Boxes represent the 
shifted NMR signals for H31 (left) and V30 (top). c,15N-1H heteronuclear NOEs for the 
amide groups of DX2-NFR in the presence of HSP70395-613 along the residue numbers. 
Heteronuclear NOE values are plotted in the scale of -1.0 to 1.0 (upper). Weighted 1H-15N 
chemical shift perturbations (CSP) (Δδ (ppm) = [0.5 × ((δH)2 + 0.2 × (δN)2)]1/2) between the 
bound and free DX2-NFRare plotted along the residue n mber (lower). 0.4 mM 15N-
labeled DX2-NFRand 4mM HSP70395-613was used in the assay. Residues from Y25 to R33 
showing positive heteronuclear NOEs and large CSP values are highlighted by the dotted box. 
d, A close-up view of the superimposed 2D 1H-15N TROSY spectra of 0.4 mM 15N-
labeled DX2-NFR (black) with 4mM HSP70395-613 (red). e, Each fragment of DX2-NFR was 
introduced into 293T cells expressing Strep-HSP70. The cell lysates were subjected to 
precipitation with a Strep-tactin column and co-precipitated DX2 was separated by SDS-











Figure 7. Determination of the binding structure of DX2 peptide on HSP70-substrate 
binding pocket.  
 
Figure 7. a, Overall dimeric structure of a chimeric protein where the24MYRLPNVHG32 of 




shown (top). The cartoon model shows a dimeric structu e in an asymmetric unit. The peptide 
sequences, MYRLPNVHG, is shown as the stick models colored by magenta and purpleblue. 
HSP70395-537 is colored by sky-blue and green. b, Difference Fourier map (Fo-Fc) at 3σ 
contour level showing the MYRLPNVHG peptide depicted as a stick model as it is situated 
in the substrate-binding pocket of HSP70. This map w s calculated by the deletion model in 
MYRLPNVHG. Residue numbers corresponding to the DX2 sequence are labeled for the 
stick model. The numbers in the parenthesis correspond to the amino acid sequence numbers 
in the chimeric protein. c, MYRLPNVHG bound to HSP70 amino acid residues. The main 
chains of HSP70 containing A406, T429 and L439 residues (blue lettering) are shown 
interacting with the peptide by hydrogen bonding, as indicated by blue dashed lines. The 
L27(541) residue of the peptide sequence is bound to the hydrophobic core comprising the 
L403, F428, V438 and I440 residues (yellow lettering) of HSP70. The bonds for involved in 
the hydrophobic interaction are depicted by the yellow dashed lines. d, Structural similarity 
of the human HSP70-DX2 chimeric protein (HSP70395-537-MYRLPNVHG) and E. coli DnaK-SBD 
containing the pyrrhocoricin-derived peptide (PDB ID: 3DPP). The carbon backbones of the 
chimeric protein and E. coli DnaK are shown in salmon and green colors, respectively. The 
MYRLPNVH sequence from DX2 binds to the substrate-binding site of HSP70 in a similar 
binding mode to that of pyrrhocoricin-derived peptide into the substrate-binding site. The 
sequences of pyrrhocoricin-derived peptide include LY-Cha-LPRPT (Cha denotes D-
cyclohexyalanine) residues29. e, Graph showing the effect of mutations in the N-terminus of 
DX2 on its binding to HSP70. Significant amino acids revealed from crystallization were 
mutated to alanine residues and the mutant proteins sted for their ability to bind to HSP70 
by an in vitro pull-down assay. Significant amino acids were colored in green. f, Strep-HSP70 




Binding of the two proteins was determined by immunoprecipitation, followed by SDS-
PAGE and Western blotting. , 293T cells expressing GFP-DX224-34 and Strep-HSP70 were 
lysed and mixed with the different amounts of NRLLLTG peptide. After immunoprecipitation 
with streptavidin-Sepharose beads, the indicated proteins were determined by 


















Figure 8. Determination of DX2 residues on GST domain involved in the interaction 





Figure 8. a, 3D structural models indicating the amino acid residues of the DX2-GST domain 
that are critical for binding, as predicted by NMR CSP analysis and mutation assays. The blue 
and red colors in the surface model indicate positive and negative charges, respectively. b, 
Superposition of the 2D 1H-15N TROSY spectra of 15N-labeled DX251-251-C136S/C222S in the 
presence (red) and absence (black) of HSP70386-543. 1D cross sections of the perturbed 
residues with or without HSP70386-543are shown in the boxes on the right. c, Mapping of the 
residues of DX2 GST that are perturbed in the presence of HSP70386-543,based on the 
decreased NMR signal intensity. The DX2 structure is represented as a backbone ribbon (left) 
and surface model (right). Strongly and weakly perturbed residues are shown in red and 
yellow, respectively. d, Schematic flow diagram for identification of DX2 residues that are 
significant for its interaction with HSP70. From NMR analysis, 4 amino acids (V54, V92, 
L97 and T117) were selected as feasible for a hydrophobic interaction and another 4 amino 
acids (H86, K121, K125 and K129) for an electrostatic interaction. L97 and T117, and K125 
and K129, which are involved in the hydrophobic and electrostatic interactions, respectively, 
were selected as the critical residues by co-immunoprecipitation. e, Validation of 
hydrophobic interaction residues of DX2 with HSP70. FLAG-DX2 mutants were 
immunoprecipitated with an anti-FLAG antibody and co-precipitation of GFP-HSP70 was 
determined by Western blotting with an anti-GFP antibody. f, Validation of electrostatic 
interaction residues of DX2 with HSP70. Indicated mutants were subjected to co-
immunoprecipitation using a Strep-tactin column. g, Quantified binding intensity was 











Figure 9. a, 3D structural models indicating the amino acid residues of the HSP70-SBD that 
are critical for binding, as predicted by NMR CSP analysis and mutation assays. The blue and 
red colors in the surface model indicate positive and negative charges, respectively. b, Close-
up view of the superposition of the 2D 1H-15N TROSY spectra of 15N-labeled HSP70386-543 in 
the presence (red) and absence (black) of full length DX2. 1D cross sections of the perturbed 
residues with or without DX2 are shown in boxes (upper right). The decreased percentages of 
the signal intensities along the residue numbers of HSP70386-543 through the DX2 binding are 
shown as a bar graph (bottom right). The residues showing more than 40% of signal 
broadening were selected for binding site mapping. c, Mapping of the residues in HSP70386-
543 perturbed by DX2 binding based on the decreased NMR signal intensity. The HSP70 
structure is represented as a backbone ribbon (left) and surface model (right). Strongly and 
weakly perturbed residues are shown in red and yellow, respectively. d, Schematic flow for 
determination of the HSP70 residues critical for DX2 binding. From NMR analysis, 4 amino 
acids (L401, L413, L486 and I503) were selected as fe ible for hydrophobic interactions 
with DX2 and another 7 amino acids (D395, E444, D481, D506, E513, E514 and E516) of 
HSP70 for electrostatic interactions. Among them, L486 and I503, and D395 and D481 were 
identified as significant residues for hydrophobic and electrostatic interactions with DX2, 
respectively, by co-immunoprecipitation assays. e, Validation of HSP70 residues involved in 
the hydrophobic interaction with DX2.Cells expressing GFP-HSP70 mutants and Strep-DX2 
were subjected to co-immunoprecipitation with an anti-Strep antibody and co-precipitated 
GFP-HSP70 was determined by Western blotting with anti-GFP antibody. f, Validation of 
HSP70 residues involved in the electrostatic interaction with DX2. Co-immunoprecipitation 
using the indicated mutants was performed with streptavidin-Sepharose beads. g, Quantified 




Figure 10. Validation of the significance of HSP70 binding for stabilization of DX2, and 
a complex model of DX2 and HSP70 binding.  
 
Figure 10. a, The effect of binding-defective mutations on HSP70-dependent stabilization of 
DX2. GFP-HSP70 was introduced into the cells expressing Strep-DX2 mutants (left) and 
GFP-HSP70 mutants were introduced into the Strep-DX2 expressing cells (right). Expressed 
proteins were determined by immunoblotting using a specific antibody against the protein tag. 
Actin was used as a loading control. b, Relative cell viability of 293T cells expressing Strep-
DX2 wild type (WT) or mutants as determined by MTT assay. Each of the tested mutations 
was represented for hydrophobic (T117A) and electrostatic (K125A) binding of GST domain 
and N-terminal region (L27A) of DX2. The experiment was independently repeated three 




on the HSP70395-537-MYRLPNVHG crystal structure and NMR binding studies. DX2 and 





















Figure 11. HSP70-mediated protection of DX2 from Siah1-mediated degradation.  
 
Figure 11. a, Endogenous binding between DX2 and Siah1 as revealed by 




Endogenous DX2 and Siah1 were precipitated with their specific antibodies in left and right 
panel experiment, respectively. b, Binding of Siah1 to DX2 in the presence of ectopically-
expressed HSP70. Strep-DX2, FLAG-Siah1, and GFP-HSP70 were expressed in 293T cells 
as indicated by labels on the top, and DX2-co-preciitated Siah1 and HSP70 were analyzed 
by SDS-PAGE and Western blotting using specific antibodies. Actin was used as a loading 
control. c, The effect of HSP70 on direct binding of DX2 and Siah1. Purified GST-DX2 was 
mixed with cell lysates expressing FLAG-Siah1 and different levels of GFP-HSP70 and 
precipitated with glutathione-Sepharose. Co-precipitated HSP70 and Siah1 were analyzed by 
SDS-PAGE and immunoblotting as described in Fig. 4bGST-DX2 was detected and 
quantified by Coomassie staining. Arrows denotes th GST proteins. d, Levels of endogenous 
DX2 was detected in 293T cells expressing FLAG-Siah1 nd GFP-HSP70 as indicated by 
labels. e-f, Determination of DX2 region mediating its binding to Siah1. (e) GFP-fusions of 
the full-length DX2 (Full) and the indicated deletion mutants (NFR, GST, and GST-C) were 
introduced into 293T cells expressing FLAG-Siah1 and precipitated with an anti-GFP 
antibody. Siah1 co-precipitated with DX2 was determined by Western blotting with an anti-
FLAG antibody. (f) Interaction regions of Siah1 and DX2. GFP-fusions f the full-length 
Siah1 (Full) and the indicated mutants (Ligase and SBD) were co-expressed in 293T cells and 
complexes containing DX2 were precipitated with strep avidin-Sepharose beads. DX2 co-
precipitating proteins were detected by Western blotting with an anti-GFP antibody. g, 
Schematic diagram of the interaction between Siah1, HSP70 and DX2. The binding regions 
of each protein are indicated by a dashed line. h, Siah1-dependent ubiquitination of DX2 in 
the presence of HSP70. HSP70 wild type (WT) or F428A mutant were introduced into 293T 




the cell lysates was precipitated with streptavidin-Sepharose beads and its ubiquitination 


























Figure 12. a, Schematic diagram of screening system using nanoluciferase assay. 
Nanoluciferase-tagged DX2 (Nanoluc-DX2) was expressed in A549 cells. The DX2 levels 
were estimated by luciferase assay after treatment with chemicals for 4 hours. b, Workflow of 
screening for selection of DX2 inhibitor, BC-DXI-495, from BC-DXI-0425. In primary 
screening for detecting the nanoluc-DX2, 34 out of 100 chemicals (library containing 
derivatives of BC-DXI-04)were selected with 60% as a cut-off value. 34 chemicals were 
subjected to secondary screenings, nanoluciferase assay for estimating level of AIMP2 and 
cell viability assay in lung cancer or normal cells. Chemicals that diminished the levels of 
AIMP2 and viability of normal lung cells were excluded. BC-DXI-495 was chosen as a hit 
chemical. c, Chemical structure of BC-DXI-495. d, A549 cells expressing each of nanoluc-
DX2 or -AIMP2 were treated with BC-DXI-495 and subjected to luciferase assay (upper). 
A549 (cancer lung) and WI-26 (normal lung) cells were treated with BC-DXI-495 as above, 
and cell viability was determined by MTT assay (bottom). The relative level of each protein 
or cell viability compared to DMSO treatment is shown as a bar graph. IC50 and EC50 values 
were calculated (under the graph). All the experiments were repeated three times and error 
bar indicates S.D. e, Effect of BC-DXI-495 (495) on DX2 protein and mRNA levels. H460 
cells were treated with the indicated amounts of BC-DXI-495 for 12 hrs. Levels of DX2 
protein and mRNA were determined by immunoblotting a d RT-PCR, respectively. Actin was 








Figure 13. PPI inhibitor, BC-DXI-495, interrupts DX2-HSP70 interaction.  
 
Figure 13. a, Effect of BC-DXI-495 on the DX2-HSP70 interaction i  293T cells. 




495 (40 μM) and precipitated with a Strep-tactin column. Co-precipitates with DX2 were 
subjected to SDS-PAGE and LC-MS analysis. A coomassie-stained gel and immunoblot 
containing immunoprecipitates (right top and bottom, respectively). Asterisk indicates HSP70 
co-precipitated with DX2 that was further validated by mass analysis (right top). The result 
was confirmed by Western blotting (right bottom). DMSO was used as a control. M denotes 
the size marker. The numbers on the left of the gel image denotes molecular weight (kDa). b, 
The ability of BC-DXI-495 to inhibit binding of DX2 and HSP70. The indicated 
concentration of BC-DXI-495 were pre-incubated with DX2 and the binding of DX2 to 
HSP70 was monitored by ELISA. c, The effect of BC-DXI-495 on Siah1-mediated DX2 
ubiquitination. 293T cells expressing Strep-DX2, FLAG-Siah1, GFP-HSP70 and HA-ub were 
treated with the indicated concentrations of BC-DXI-495. After immunoprecipitation of 
Strep-DX2, the amounts of ubiquitination and binding of DX2 were determined by SDS-

















Figure 14. a, The effect of BC-DXI-495 on cell viability in DX2-expressing A549 cells. The 
MTT assay was used to determine cell viability in DX2-inducible A549 cells (ind-DX2) after 
doxycycline (Dox+) and BC-DXI-495 (495+; 40 μM) were added at the indicated time. 
DMSO was used as a negative control for BC-DXI-495. Ind-EV denotes the empty vector-, 
negative control for DX2, inducible A549 cells. b, In DX2-inducible cells treated with 
doxycycline and 495 as indicated, DX2 and HSP70 levels were determined by Western 
blotting with their specific antibodies. Actin was u ed as a loading control. c, The EC50 of 
BC-DXI-495 in lung cell lines expressing different levels of DX2, The EC50 of BC-DXI-495 
in lung cancer and normal cell lines (WI-26 and WI-38) expressing various level of DX2 
(low to high, as indicated on the right) was determined by the MTT assay. The relative 
EC50values were graded from 0 to 10, as represented in the heat map. d-j, The effect of BC-
DXI-495 on cancer progression in an i  vivo mouse xenograft model. H460 cells were 
subcutaneously xenografted in nude mice, and BC-DXI495 (50 mg/kg) was intraperitoneally 
administered for 2 weeks. Tumor size (e) and body weight (g) were monitored for the period 
of injection. Photos of the tumor-bearing mice and excised tumors (d) and bar graph showing 
tumor weight (f). The cellular levels of the indicated proteins in excised tumors were 
analyzed by Western blotting using their specific antibodies. The number of mouse was 
indicated on top (j). All the experiments were independently repeated three times and the 








Figure 15. Significance of BC-DXI-495 on DX2 binding. 
 
Figure 15. a, H460 cells were treated with 4 other biotinylated BC-DXI-495 (Biotin-495) 
and endogenous level of DX2 was determined by immunoblotting. Actin was used as a 
loading control. b, Specificity of BC-DXI-495 (495) binding to DX2. Biotin-495 was mixed 




precipitated with biotin-495 in an i  vitro pull-down using streptavidin-Sepharose beads were 
subjected to SDS-PAGE and Western blotting using anti-GFP antibody. Biotin was used as a 
negative control for biotin-495. Arrows denotes GFP-tagged proteins. c, Strategy of LC-MS 
analysis for confirmation of interaction between BC-DXI-495 and DX2. Biotin-495 was used 
to compete with BC-DXI-495. After pull-down with biot n-495, the abundance of DX2 in the 
precipitates was analyzed by mass spectrometry and represented as a bar graph. d, Purified 
DX2 proteins were immobilized and multiple concentration of BC-DXI-495 were flowed for 
















Figure 16. Mode of action of BC-DXI-495 on DX2.  
 
Figure 16. a, Detection of BC-DXI-495 binding region of DX2 using an NMR-based 
chemical shift perturbation (CSP) assay. Superposition of the 2D 1H-15N TROSY spectra of 
15N-labeled DX251-251-C136S/C222S in the presence (red) and absence (black) of BC-DXI-495. 




DX2 GST domain that are perturbed in the presence of BC-DXI-495,based on the decreased 
NMR signal intensity and CSP, represented as a backbone ribbon model (left) and surface 
model (right). Strongly perturbed residues are shown in red. c, Identification of DX2 residues 
critical for binding to BC-DXI-495. 293T cells expressing each of the Strep-DX2 alanine-
substitution mutants were treated with BC-DXI-495. Strep-DX2 proteins in the cell lysates 
were isolated by immunoprecipitation with streptavidin-Sepharose beads. d, Docking of BC-
DXI-495 in the DX2 GST domain based on the NMR CSP analysis and mutation assay. 
Residues led to loss of binding via mutation are represented on the backbone model (upper) 
and surface model (bottom) in red. e, Proposed model of the DX2 and HSP70395-537 complex 
based on the HSP70395-537-MYRLPNVHG structure and NMR binding studies. DX2 and HSP70395-
537 are represented as sky-blue surface and pale-yellow ribbon models, respectively. The line 
model represents the DX2 N-terminal (residues 1-23) and linker region (residues 33-50). The 
N-terminal M24-G32 residues of DX2 were represented as stick model. The BC-DXI-495 











Figure 17. Significance of BC-DXI-495 binding on DX2 in in vivo model.  
 
Figure 17. a-e, H460 cells stably expressing FLAG-DX2 wild type (WT) or the DX2 L80A 
mutant were subcutaneously injected into the backs of nude mice and BC-DXI-495 (50 
mg/kg) was injected intraperitoneally for 15 days. The tumor volume (b) and body weight (d) 




weighed after sacrifice of the mice (c), and the protein levels of FLAG-DX2, HSP70 and 





















Table 1. List of the DX2 top50 interactome 
  
* The protein list is sorted according to the fold change. 
  
   




Bifunctional aminoacyl-tRNA synthetase EPRS 4640.0 
Aspartyl-tRNA synthetase, cytoplasmic DARS 3563.3 
Isoleucyl-tRNA synthetase, cytoplasmic IARS 3193.3 
aminoacyl tRNA synthetase complex-interacting multif nctional protein 2 AIMP2 2370.0 
heat shock 70kDa protein 8 HSPA8 1960.0 
heat shock 60kDa protein 1 (chaperonin) HSPD1 1944.5 
leucyl-tRNA synthetase LARS 1656.7 
actin, gamma 1 ACTG1 886.7 
methionyl-tRNA synthetase MARS 840.0 
Isoform Cytoplasmic of Lysyl-tRNA synthetase KARS 806.7 
78 kDa glucose-regulated protein HSPA5 603.3 
Stress-70 protein, mitochondrial (mortalin) HSPA9 510.0 
arginyl-tRNA synthetase RARS 506.7 
ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide ATP5B 496.7 
Isoform 1 of Clathrin heavy chain 1 CLTC 443.3 
T-complex protein 1 subunit alpha TCP1 350.0 
chaperonin containing TCP1, subunit 7 (eta) CCT7 333.  
heat shock 105kDa/110kDa protein 1 HSPH1 330.0 
Mitochondrial import inner membrane translocase subunit Tim13 TIMM13 320.0 
splicing factor 3b, subunit 3, 130kDa SF3B3 316.7 
glutaminyl-tRNA synthetase QARS 303.3 
chaperonin containing TCP1, subunit 6A (zeta 1) CCT6A 276.7 
Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 AIMP1 266.7 
Isoform 1 of Protein-L-isoaspartate(D-aspartate) O-methyltransferase PCMT1 260.0 
dihydrolipoamide branched chain transacylase E2 DBT 240.0 




GrpE protein homolog 1, mitochondrial GRPEL1 230.0 
ATPase, Na+/K+ transporting, alpha 1 polypeptide ATP1A1 230.0 
carbamoyl-phosphate synthetase 2, aspartate transcabamylase, and 
dihydroorotase 
CAD 220.0 
cDNA FLJ56386, highly similar to Heat shock 70 kDa protein 1L HSPA1L 200.0 
ataxin 2-like ATXN2L 186.7 
heat shock 70kDa protein 2 HSPA2 176.7 
filamin A, alpha FLNA 173.3 
heat shock 70kDa protein 4 HSPA4 170.0 
damage-specific DNA binding protein 1, 127kDa DDB1 170.0 
ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, 
cardiac muscle 
ATP5A1 166.7 
Proteasome subunit beta type-1 PSMB1 160.0 
Isoform 1 of Filamin-B FLNB 153.3 
proteasome (prosome, macropain) 26S subunit, non-ATPase, 1 PSMD1 150.0 
Proteasome subunit beta type-3 PSMB3 146.7 
apoptosis-inducing factor, mitochondrion-associated, 1 AIFM1 146.7 
Heat shock 70 kDa protein 1A HSPA1B 143.4 
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 ATP2A2 143.3 
cDNA FLJ56389, highly similar to Elongation factor 1-gamma EEF1G 140.0 
Proteasome 26S non-ATPase subunit 11 variant (Fragment) PSMD11 136.7 
proteasome (prosome, macropain) subunit, alpha type, 4 PSMA4 133.3 
WD repeat domain 82 WDR82 130.0 
33 kDa protein RPSA 126.7 
26S proteasome non-ATPase regulatory subunit 2 PSMD2 126.7 
leucine-rich pentatricopeptide repeat containing LRPP C 113.3 







Table 2. Data collection and Refinement statistics 
 
HSP70 394-537-MYRLPNVHG 
Wavelength (Å) 0.9795 
Resolution (Å) 28.08 - 1.79 (1.854 - 1.79) 
Space group P 21 21 21 
Unit cell 41.111 77.054 88.711 90 90 90 
Total reflections 211834 (19718) 
Unique reflections 27052 (1776) 
Multiplicity 7.8 (8.0) 
Completeness (%) 94.56 (66.54) 
Mean I/sigma (I) 10.42 (2.52) 
Wilson B-factor 17.31 
R-merge 0.1388 (0.8994) 
Refinement  
Reflections used in refinement 25781 (1776) 
Reflections used for R-free 2000 (138) 
R-work 0.1835 (0.2819) 
R-free 0.2194 (0.3337) 
Protein residues 305 
RMS (bonds, Å) 0.006 
RMS (angle, °) 0.95 
Ramachandran favoured, allowed (%) 100.00 
Ramachandran outliers (%) 0.00 
Rotamer outliers (%) 0.76 
Statistics for the highest-resolution shell are shown in parentheses. 
 
R-work is the conventional crystallographic R factor, ∑|FO-FC|/∑|FO|;FO and FC mean the 



























The chaperone activities of HSPs have attracted much attention as potential cancer therapy 
targets7. However the ability to specifically control the pathologic activities of HSPs without 
affecting their physiological roles in protein folding remains challenge. Here, I show one 
example of how a tumor-promoting interaction of HSPs can be specifically controlled. While 
HSP70 traditionally has been known as a helper that delivers protein clients to HSP9012, 
recent reports have shown that HSP70 also can function as a chaperone independently of 
HSP9014,33. In addition to its inherent chaperone activity, studies have also suggested that 
HSP70 protects the client from physical attack, access of E3 ligase, through an interaction 
with HSP70’s SBD14. The underlying mechanism for this interaction, is not yet well 
understood. However, to this end, the structural anlysis presented herein shows that the 
binding of the substrate-binding domain of HSP70 to the N-terminal flexible region and GST 
domain of DX2 protects DX2 from Siah1-mediated ubiqitination. Moreover, preventing 
HSP70 binding to DX2 by mutational and chemical inhibition destabilized DX2, suggesting 
HSP70 is functionally significant in maintaining cellular levels of DX2.  
The binding between DX2 and HSP70 takes place in two phases. In the first phase, 
the NFR of DX2 accesses the substrate-binding pocket of the HSP70’s SBD through 
hydrophobic interactions, as visualized by x-ray crstallography (Fig. 7). I determined that 
the Y25 and L27 residues of DX2 and L403, F428, V438 and I440 residues of HSP70 are 
potentially important for hydrophobic interactions. The substrate-binding pocket in HSP70’s 




the N-terminal sequence of DX2 differs from the canonical sequence of HSP70 substrates, a 
few hydrophobic amino acids in DX2-NFR such as Y25 and L27 appear to play crucial roles 
in HSP70 binding. Determined binding mode of DX2-NFR’s hydrophobic peptide region is 
highly similar to the pyrrhocoricin-derived peptide that tightly binds to DnaK (PDB 3DPP)29. 
In addition, the F428 residue of HSP70, which is a well-known hydrophobic residue involved 
in client recognition, was also determined crucial for the interaction with DX2-NFR, 
suggesting that HSP70 uses the consensus-binding mode11,34in its recognition of DX2. 
The second phase of binding involves the β-sheet surface in the DX2 GST domain 
and the hinge region between the α-helical Lid and β-stranded SBD of HSP70 (Fig. 8-9). The 
DX2’s L97 and T117 residues and HSP70’s L486 and I503 residues participate in a 
hydrophobic interaction while DX2’s positively charged K125 and K129 residues and 
HSP70’s negatively charged D395 and D481 residues participate in an electrostatic 
interaction. The DX2-GST domain and HSP70-SBD are lik ly precisely positioned through 
electrostatic interaction and bind with strong affinity through the hydrophobic interaction. 
Our structural model based on the x-ray and NMR data herein provides critical information 
on how HSP70 could recognize its clients and protect hem from ubiquitin-mediated 
degradation (Fig. 10c).  
Here I clearly demonstrated that Siah1 functions as the E3 ligase for DX2 
ubiquitination, extending earlier observation that the levels of DX2 and Siah1 are negatively 
correlated32. Our data also shows that Siah1 binding to DX2 wascompetitively blocked by 
HSP70. While the competitive regulation between HSP70 and Siah1 appears to maintain the 
appropriate cellular levels of DX2, the high levels of HSP70 in cancer cells may lead to 




is structurally disordered, it is vulnerable to protease attack and ubiquitination-mediated 
degradation. Binding of this peptide region to the substrate-binding pocket of HSP70-
SBDmay protect DX2 from ubiquitination by Siah1, leading to high levels of DX2. Whether 
HSP70 binding to DX2 also mediates proper folding will be the focus of future studies. 
Given its high levels of expression in cancer cells and tumorigenic activities, DX2 
can be considered a promising target for cancer therapies. However, finding ways to suppress 
its expression or activity has been challenging for its structural disorder and lack of 
stabilizing mechanism. Thus, our identification of a specific, tumor-promoting interaction 
between HSP70 with DX2has provided a novel and attractive target point. This concept was 
validated by our demonstration that chemical inhibition of the DX2-HSP70 interaction 
suppressed DX2-induced tumor growth. This result also provides insight into potential 
mechanisms for specifically controlling the activities of HSPs. While HSPs could also serve 
as attractive cancer targets, inhibiting chaperone activities might cause adverse effects since 
their clients include numerous cellular factors. However, here I demonstrated the fine control 
of HSP70 activity by specifically blocking one particular client, DX2. Clinical application of 












Cell culture and materials. H522, H1435, H460, SW900, H1793, H854, H358, H727, H23, 
HCC-1438, HCC-1195, H441, H1299, Calu-6, HCC-1588, HCC-1359, HCC-366, WI-26, 
HCC-95, H1755, H226, SK-LU-1, WI-38, HCC-2279, H1650, H2087, H1666, SK-MES-1, 
NCI-H1792 and 293T cell lines were purchased from ATCC and the Korea Cell Line Bank. 
293T cells and other cell lines were cultured in DME  and RPMI supplemented with 10% 
FBS and 1% penicillin/streptomycin, respectively, and grown in 5% CO2 at 37°C. GFP-
tagged HSP70 (#15215) and HSP90 (#108221) were purchased from Addgene. The gene 
encoding DX2 was cloned into the EcoRI/XhoI sites of pEXPR-IBA5, pEGFP-C2 and 
pcDNA3.0 vectors. FLAG-tagged Siah1 was purchased from the Korea Human Gene Bank, 
Medical Genomics Research Center, KRIBB. Mutagenesis of DX2 and HSP70 was 
performed with Quik-ChangeII (Promega), following the manufacturer’s instruction. 
Cycloheximide, MG-132, and okadaic acid were purchased from and Sigma. The procedure 
for preparing the anti-DX2 antibody and its characterization will be provided upon request. 
Specific antibodies against Strep and FLAG were purchased from IBA and Sigma, 
respectively, and other antibodies used in this study were purchased from Santa Cruz 
Biotechnology. 
 
Protein preparation. DX2 (residues 1-251), DX21-50, and DX251-251-C136S-C222S were cloned 
into yeast Small Ubiquitin-like modifier (SUMO)-modified pET28a vector (yeast SUMO-




prepare the epitope-tagged version of SUMO, His-SUMO. The DX2 sequence was inserted 
between the BamHI and XhoI sites of the vector. The plasmid was transformed into 
E.coli BL21-Codon Plus(DE3)-RIPL (Stratagene, USA), cells were grown in Luria-Bertani 
(LB) media (Merck Millipore) at 18°C, and expression was induced by 0.5 mM isopropyl β-
D-1-thiogalactopyranoside (IPTG). The cells were harvested and disrupted in lysis buffer 
(50 mM Tris-HCl pH 7.4, 500 mM NaCl, 7 mM β-mercaptoethanol, 1 mM PMSF and 10% 
glycerol). After centrifugation at 32,500×g for 60 min, the His-SUMO fused DX2 was 
purified using Ni-NTA column chromatography using 50 mM Tris-HCl pH 7.4, 500 mM 
NaCl, 40mM imidazole as the equilibrium buffer. After elution with 500 mM imidazole, the 
His-SUMO tag was cleaved by the SUMO protease Ulp1. The tag-free version of DX2 was 
concentrated by ultrafiltration and further purified by size exclusion chromatography using a 
Superdex 75 16/60 column (GE Healthcare, UK) equilibrated with a buffer containing 
25 mM Tris-HCl pH 7.4, 150 mM NaCl, 7 mM β-mercaptoethanol, 0.1 mM EDTA and 1 mM 
PMSF. Human HSP70, HSP701-613, HSP70386-543, HSP70395-543, HSP70395-613, HSP70395-537-
MYRLPNVHG were cloned and purified using the same protocol as for DX2. NRLLLTG peptide 
was synthesized and provided by the Korea Basic Science Institute (KBSI) 
 
Protein crystallization and data collection. Crystallization of the chimeric HSP70395-537-
MYRLPNVHG protein was initially performed with the JBScreen wizard (Jena Bioscience) using 
the sitting-drop vapor diffusion method, and was optimized by the hanging-drop vapor 
diffusion method at 20°C. After optimization, the bst crystal was obtained under reservoir 
conditions of 25% PEG1500, 15 mM SPG (pH 5.5) in drops where 1.2 μl of protein solution 




protectant solution containing an additional 10% glucose in the crystallization solution, prior 
to x-ray diffraction data collection. The diffraction screening and data collection were 
performed by using the CCD detector, ADSC Q315r andQ270, at beamline 5C and 7A at 
Pohang Accelerator Laboratory (PAL), respectively (Pohang, Korea). The HKL2000 was 
used for data processing, involved index, and integration and merging35. This crystal belongs 
to the space group P212121. The unit cell dimensions are a=41.111, b=77.054, c=88.711 and 
α=β=γ=90°. This structure contains two protein monomers in an asymmetric unit.  
 
Structure determination and refinement. The structure of the human HSP70-DX2 chimera 
protein (HSP70395-537-MYRLPNVHG) was determined by molecular replacement and refinement 
using the PHENIX program36. The Coot37 and PHENIX program were also used for modeling 
and structural refinement, respectively. A model published by another group (PDB ID: 4WV5) 
was used as an initial model for molecular replacement38. PHENIX and CCP4i were used to 
generate of each of maps, including the composite-omit map for refinements39. The final 
structure of the human HSP70-DX2 chimera protein was determined at 1.79Å resolution. 
Statistics of the intensity data and the refinement are summarized in Table 2. 
 
NMR spectroscopy. The 15N-labelled proteins were prepared by growing the bacterial cells 
in M9-minimal media enriched with 15NH4Cl as the sole nitrogen source (99% 
15N; 
Cambridge Isotope Laboratories). Protein expression and purification were carried out as 
described above. Protein samples were dialyzed overnight at 4°C against a buffer containing 
20 mM Bis-Tris pH 6.0, 150 mM NaCl, 7 mM β-mercaptoethanol, 0.1 mM EDTA and 1 mM 




spectrometer (Bruker, Germany). For the binding and competition experiment using the DX2, 
HSP70 and NRLLLTG peptide, the 1H-15N TROSY (transverse relaxation optimized 
spectroscopy) experiments were performed after a 1day at 4°C incubation of 0.2 mM 15N-
labeled full length DX2 (DX21-251) in the absence and presence of 0.1 mM full length HSP70 
(HSP701-641). Then, we added the mixture of 1 mM NRLLLTG peptide and 0.1 mM HSP701-
641 after incubation at 4°C for 1 day to 0.2 mM 
15N-labeled DX21-251 and performed 
1H-15N 
TROSY. As a control experiment, 1H-15N TROSY was performed on a mixture of 0.2 
mM 15N-labeled DX21-251 and 1 mM NRLLLTG peptide. To determine the region of DX2 that 
bind to HSP70386-543, 
1H-15N TROSY experiments were performed on 0.4 mM 15N-
labeled DX2-NFDin the presence and absence of 4 mM HSP70395-613 after incubating the 
mixture at 4°C for 1 day. Steady-state 15N-1H-heteronuclear NOE spectra were measured with 
either 10-s delays between each free-induction decay or 6-s delays followed by a 4-s series of 
nonselective 1H pulses. 15N-1H NOE experiments were performed with time-domain sizes of 
152 × 2048 complex points. A 25% non-uniform sampling (NUS) schedule was applied and 
sweep widths of 6009.615 Hz and 1338.330 Hz were set along the 1H and 15N dimensions, 
respectively, with 64 scans for the experiment. Data were processed with MddNMR (version 
2.5) in the NmrPipe environment. 15N-1H-heteronuclear NOE values were calculated from the 
ratio of peak intensities, Isat/Iunsat, where Isat and Iunsat represent the intensities of peaks in 
saturated and unsaturated spectra, respectively. To determine the binding region of DX2 with 
BC-DXI-495, the 1H-15N TROSY experiments were performed with 0.2 mM 15N-
labeled DX21-251 with 0.5% DMSO in the presence and absence of 0.2 mM BC-DXI-495.  
 




simulations were performed with the HADDOCK program40 using the energy minimized 
atomic coordinates of the DX2 GST domain (PDB ID 5A34) and HSP70 substrate binding 
domain from the structure of HSP70395-537-MYRLPNVHG. For HADDOCK calculations, the N56, 
L80, S81, H84, T85, S87, L97, G115, L118, I119, W120, K121, M128 and K129 residues of 
the AIMP2 GST domain were treated as active residue, and the S400, L401, L413, R416, 
N417, D479, A482, N483, G484 and L486 residues of the human HSP70 substrate-binding 
domain were treated as active residues based on the CSP data. The active residues were 
treated as flexible in the docking simulation. The remaining residues in the interfaces were 
treated as passive. The most stable structure of the major populated first cluster was used for 
analysis. 
 
Docking of BC-DXI-495 on the structure of DX2. Structure of DX2-GST obtained from 
PDB 5A34 was energy minimized and prepared for docking using Gasteiger charge, protein 
structure was kept rigid in docking and BC-DXI-495 binding site was defined from CSP 
mapped residues obtained from NMR binding experiments. Dimensions of a grid with 72 × 
54 × 64 points and 0.375 Å grid spacing were used for the sampling of ligand conformations. 
BC-DXI-495 was modeled with SYBYL-X 2.0 molecular modeling 
package(http://tripos.com), and energy minimized with Gasteiger-Hückel charge setin 
vacuum dielectric environment, using Powell algorithm and Tripos force field for 5000 
iterations subject to a termination gradient of 0.05 kcal/(mol·Å). Energy minimized BC-DXI-
495 was prepared for Autodock, Gasteiger charges were assigned. Autodock4.241 
(http://autodock.scripps.edu/) was used to sample 200 docking poses of ligand. Ligand 




independent runs, an initial population of 150 randomly placed individuals, with 2.5 × 106 
energy evaluations, a maximum number of 27000 iterat ons, a mutation rate of 0.02, a 
crossover rate of 0.80, and an elitism value of 1. A representative docking pose was selected 
from the highest populated cluster. PyMOL42 (http://www.pymol.org) was used for manual 
inspection of distances. 
 
Chemical library generation and chemical probe synthesis. Previous study reported that 
four chemicals were identified as a DX2-inhibitory chemicals from the screening the 
ChemDiv’s library. Four chemicals were named BC-DXI-01~04, and BC-DXI-04, a 
sulfonamide type chemical, was selected for further study in this research. Of note, 
sulfonamides are significant class of synthetic comp unds that are present in various drugs or 
drug candidates targeting diuretics, antibiotics, caner, or inflammation43. Accordingly, in-
house chemical library was constructed, including derivatives of BC-DXI-04, and BC-DXI-
495 was chosen as a novel lead. In addition the chemical probes of BC-DXI-495 were 
designed and prepared for further mechanism study.  
 
Mass spectrometry. 293T cell lysates (5 mg) expressing Strep-empty vector (EV) or -DX2 
were subjected to Strep-tactin column chromatography. Elutes were digested by in-gel 
digestion using trypsin/Lys-C (Promega). After purification of tryptic peptides using a C18 
spin column, the peptide mixture was subjected to analysis using LTQ-Orbitrap Velos 
(Thermo Fisher Scientific) connected to an Easy-nano LC II system (Thermo Fisher 
Scientific) that incorporated an autosampler. One-tenth of the peptides re-suspended in 0.1% 




μm, 5 μm, 120 Å, ReproSil-Pur C18-AQ, Thermo Fisher Scientific) and a reversed-phase 
analytical EASY-Column (L 10 cm, ID 75 μm, 3 μm, 120 Å, ReproSil-Pur C18-AQ, Thermo 
Fisher Scientific). Electrospray ionization was subsequently performed using a 30 μm nano-
bore stainless steel online emitter (Thermo Fisher Scientific). The total duration of LC 
gradient procedure was 120 min. The LTQ-Orbitrap Velos mass analyzer was operated in 
positive ESI mode using collision induced dissociation (CID) to fragment the HPLC 
separated peptides. The data were analyzed with Sequest (XCorr Only) (Thermo Fisher 
Scientific, San Jose, CA, USA; version v.27, rev.11) and X! Tandem (The GPM, thegpm.org; 
version CYCLONE (2010.12.01.1)) using a human database (Uniprot human, release 2014). 
Scaffold program (version 4.6.1, Proteome Software Inc., Portland, OR) was used to validate 
the MS/MS-based peptide and protein identifications a d to process the quantitative analysis. 
For identifying the BC-DXI-495-binding protein, GFP-DX2-expressing 293T cells treated 
with BC-DXI-495 were lysed and the lysates subjected to pull-down using a Strep-tactin 
column. Proteins in the elutes were analyzed as above. To validate the binding of BC-DXI-
495 to DX2, 293T cells expressing GFP-tagged DX2 were s rially treated with BC-DXI-495 
and biotinylated BC-DXI-495. The biotinylated chemicals were pulled down and co-
precipitates analyzed by the same protocol as describ d above. 
 
Surface plasmon resonance (SPR) analysis. The binding affinity of BC-DIX-495 to DX2 
was measured using a Reichert SR7500DC instrument (Reichert Technologies, Depew, NY). 
To determine the binding affinity between DX2 and BC-DXI-495, TRX-DX2 and TRX was 
immobilized at levels of 5580 and 2000RU, respectivly, with 10 mM sodium acetate buffer 




containing PBS binding buffer (pH 7.4) was flowed at a rate of 30 μl/min. Sensorgrams were 
fitted to a simple 1:1 Langmuir interaction model (A + B  AB) using the Scrubber 2.0 ⇌
analysis program (BioLogic Software, Australia, and Kaleida Graph Software, Australia). 
 
Xenograft. DX2 wild type (WT) and L80A mutant were cloned into pcDNA3.0 and 
expressed in H460 cells cultured for two weeks in the presence of 800 μg/mlG418 (Duchefa). 
After selection, the settled colonies were picked an the level of overexpressed proteins was 
evaluated by immunoblotting using an anti-FLAG antibody. The cells (2 x 107) stably 
expressing DX2 WT and the L80A mutant were subcutaneously inoculated into the left and 
right sites of the back of 7-weeks-old female BALB/cAnCr mice (n=3 / group), and BC-DXI-
495 (50 mg/kg) was intraperitoneally administrated very other day for 15 days. The 
embedded tumor sizes and body weights were measured two times a week for the 
experimental period. All the mice were sacrificed and the size and weight of the embedded 
tumor were measured after photos of mice were taken. Animal experiments were in 
compliance with the University Animal Care and Use Committee guidelines at Seoul 
National University. 
 
Immunohistochemistry staining. Tissue micro array (TMA) slides (US Biomax, Inc.) 
containing lung tumor and matched normal tissues from same patients were deparaffinized 
and rehydrated in different percentages (100, 95, 80 and 70%) of ethanol. To remove the 
endogenous peroxidases and retrieve the antigen samples were incubated with PBS 
containing 0.3% H2O2 (Sigma) for 10 minutes and 10 mM citric buffer (pH 6.0) at 95°C for 5 




were incubated with the primary antibodies, DX2 or HSP70 (Novusbio), at 4°C for 12 hours 
and anti-rabbit- or -mouse-HRP (Dako) for 1 hour, respectively. A 3,3′-Diaminobenzidine 
(DAB) and Chromogen mixture (Dako) was used to develop the slides and nuclear counter 
staining was performed with Mayer’s hematoxylin (Sigma). The slides were dehydrated with 
different concentrations of ethanol (70, 80, 90 and 100%) and then mounted. The staining 
intensity of the proteins was graded to 0 (<5% positive), 1 (5-40% positive), and 2 (>40% 
positive). The numerical grade was confirmed by a second independent examination. 
 
In vitro pull-down assay. Cell lysates expressing the GFP-tagged proteins were mixed with 
purified GST-tagged proteins in 50 mM Tris-HCl (pH 7.4) binding buffer containing 100 mM 
NaCl, 0.5% Triton X-100, 10% glycerol, 1 mM EDTA, and protease inhibitor (Calbiochem) 
and incubated for 12 hours at 4°C. After incubation, the GST proteins were precipitated using 
glutathione Sepharose beads and washed with binding buffer three times. Proteins that co-
precipitated with GST proteins were then subjected to SDS-PAGE. The amounts of GFP-
tagged proteins were determined by immunoblotting with a GFP-specific antibody and 
amounts of GST-tagged proteins were determined by Coomassie staining.. 
 
Enzyme-linked immunosorbent assay (ELISA). Purified DX2 protein (150 ng/well) was 
coated on a flat-bottom 96-well plate (Thermo) in 0.05M sodium carbonate buffer (pH 9.6). 
After washing with PBST (0.05% Tween20), PBST including 1% BSA solution was used for 
blocking for 1 hour at room temperature. The plates w re pre-incubated with diluted BC-
DXI-495and purified HSP70 (150 ng/well) was added to the wells for the binding reaction. 




sequentially bound for overnight and 1 hour, respectiv ly. After washing, 3,3',5,5’-
tetramethylbenzidine (TMB) solution (Thermo) was adde  for the detection of bound HSP70 
and incubated for 10 minutes. The reaction was thenstopped by the addition of 1N H2SO4 
and absorbance was evaluated at 450 nm (Ref: 620 nm). 
 
Co-immunoprecipitation. H460 cells were lysed with 50 mM Tris-HCl (pH 7.4) lysis buffer 
containing 100 mM NaCl, 0.5% Triton X-100, 0.1% SDS, 10% glycerol, 1 mM EDTA, and 
protease inhibitor (Calbiochem). The cell lysates were mixed with HSP70 antibody that was 
pre-incubated with agarose G for 12 hours and washed t ree times with cold lysis buffer 
excluding 0.1% SDS. 293T cells expressing Strep- and GFP-tagged proteins were lysed as 
described above and Strep-tagged proteins were precipitated with a Strep-tactin column 
(IBA), following the manufacturer’s instruction. Co-precipitates with bait proteins were 
separated by SDS-PAGE and subjected to Western blotting with specific antibodies to the 
proteins of interest. 
 
Anchorage-independent colony formation assay. The Strep-empty vector (EV) or Strep-
DX2 was introduced into H460 cells stably expressing sh-con or sh-HSP70 (Santa Cruz 
Biotechnology). The cells were subjected to anchorage-independent colony formation assay 
using a cell transformation assay kit (CELL BIOLABS, INC.), following the manufacturer’s 
instruction. After culturing the cells for 1 week, the number of colonies stained by MTT 





MTT assay. H460 cells (1 x 104) were cultured in 96 well plate for 24 hours. 10 μl of MTT 
solution (5 mg/ml, Sigma) was added to each well and incubated for 1.5 hour at 37 °C. The 
precipitated formazan crystals were dissolved with 100μl DMSO (Duchefa) after discarding 
the cell culture media. Absorbance was measured at 560 nm using a micro plate reader 
(Sunrise, TECAN). The experiments were repeated three times independently. 
 
EdU assay. The Strep-empty vector (EV) or -DX2 was introduced into 293T cells grown on 
coverslips in 24 well plates that expressed si-HSP70 (Santa Cruz Biotechnology).After 
determining the levels of DX2 and HSP70 by Western blotting using specific antibodies to 
the proteins, the cells were subjected to an ethynyldeoxyuridine (EdU) assay using the EdU 
Cell Proliferation Assay kit (Merck), following the manufacturer’s instruction. DAPI was 
used for staining the nuclei. The fluorescence signal was detected by confocal microscopy 
and quantified for equal numbers of cells. The experim nts were repeated three times 
independently. 
 
RT-PCR. Total RNA from H460 cells was extracted using an RNeasy Mini Kit (Qiagen) and 
subjected to RT-PCR with dNTP, random hexamer and Moloney murine leukemia virus 
(MMLV). The same volume of RNA was used in a PCR assay to detect the mRNA expression 
of DX2, HSP70, and Actin using the following specific primers: 
DX2: CTGGCCACGTGCAGGATTACGGGG and AAGTGAATCCCAGCTGAT G; 
HSP70: GTCGTCCAGCACCCAGGCCAGC and GCTCTTGTTCAGGTCGCGCCCG; 
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Enhanced productive folding of a translated polypeptid  via heat shock protein 70 (HSP70) is 
often required for survival of cancer cells. Although the folding activity of HSP70 is 
considered a significant determinant for progression of cancer cells, it is still unknown how 
this activity could be regulated. Here, I report the phosphorylation of HSP70 that facilitates 
its folding activity, enhancing cell proliferation. Mass spectrometry confirmed serine residues 
at positions 385 and 400 on the linker and substrate-binding domain of HSP70, respectively, 
as the phosphorylation sites upon EGF signal, and this result was further confirmed by site-
directed mutagenesis. ERK is discovered to be a specific kinase. Phosphorylation of the two 
sites induces the extended conformation of HSP70 via control the binding of linker to 
nucleotide- and substrate-binding domain, augmenting the binding affinity of substrate to 
HSP70 and folding activity, resulting in pro-proliferative function. Cell lines harboring 
activated ERK basically showed the phosphorylation of HSP70,and a positive correlation 
between phosphorylation of HSP70 and activity of ERK was observed. Thus, this study 
demonstrates that ERK-dependent phosphorylation of HSP70 facilitates its folding activity 
and cellular proliferative function. 
 
Keywords: HSP70, ERK, phosphorylation, conformational change, folding, proliferation 
 






The 70-kDa heat shock protein (HSP70) is a family of ubiquitous molecular chaperone 
proteins that play an important role in protein folding and protecting the cell from the heat 
shock and toxic stresses1,2. In addition to its canonical function, HSP70 is criti al for cell 
proliferation, apoptosis and protein degradation in various diseases, especially cancer, and 
thus, it has been considered as a potential target for anticancer therapeutics3-5. HSP70 is 
composed of two other highly conserved domains, nucleotide-binding domain (NBD) and 
substrate-binding domain (SBD), which are connected via a flexible linker6. SBD is further 
divided into the two parts; one is SBDβ, which is existing substrate-binding pocket for 
binding with the client, and the other is SBDα, called lid, which is involved in tightening the 
binding of client7. For proper folding of client protein, HSP70 undergoes two conformational 
changes, adenosine triphosphate (ATP)- and adenosine diphosphate (ADP)-bound form6. 
When client binds with the SBD of ATP-bound form, HSP70 conducts hydrolysis of ATP, 
inducing the conformational change to ADP-bound form, closing and exposing the lid and 
linker, respectively7,8. After the release of properly folded protein, HSP70 again transforms to 
ATP-bound form followed by reduced linker dynamics7,8. Although only fine-tuning of the 
nucleotide-dependent cycling of HSP70 conformation has been studied as a determinant of 
protein folding, recently, a new aspect, post-translational modification, has also attracted 
attention for regulation of the function of HSP70. 
Phosphorylation among the various post-translational modifications is transient, 




Phosphorylation of HSP70 has been slightly unraveled in various cellular contexts by a few 
studies. During protein translation, phosphorylation of HSP70 regulates its dimerization or 
protein degradation via HSP70-binding protein, CHIP10,11. Regulation of cell cycle and 
apoptosis via phosphorylation of HSP70 has been already reported, an  phosphorylation of 
HSP70 was explored in terms of chemoresistance of cancer cells12,13.Studies on 
phosphorylation of HSP70 are focused on phosphorylation in NBD and SBD because of 
unawareness of the significance about linker, which is critical for regulating the activity of 
HSP70. However, several reports have recently focused on the fine-tuned dynamics of 
HSP70 via linker8,14. Here I report the phosphorylation sites, serine 385 and 400, on the linker. 
Both the phosphorylation sites are phosphorylated by ERK upon EGF signal and induce the 
extended conformation of HSP70. Phosphorylation-dependent extended conformation leads 















ERK phosphorylates HSP70 
Augmented productive folding of the translated peptides is very important for the enhanced 
proliferation capacity of cancer cells4. Although the level of heat shock proteins in cancer 
cells is not associated with successful folding, the ranslated peptides are folded well17,18. 
Since the activity of HSP70 in cancer cells has been r ported to be increased by 
phosphorylation, I investigated whether HSP70 is phos orylated via EGF signaling pathway, 
critical for cancer progression19,20. Using immunoprecipitation on the cells expressing Strep-
HSP70, it was monitored that the serine residues of HSP70 are phosphorylated via EGF 
signaling (Fig. 1a). To determine the kinase responible for phosphorylation of HSP70, I 
treated the cells with several inhibitors, U0126, SB203580, SP600125 and LY294002, for 
targeting the downstream kinases of EGF signal pathway21. EGF-dependent phosphorylation 
on serine residues of HSP70 was diminished by treatm nt with only U0126, inhibitor of 
mitogen-activated protein kinase kinases, MEK-1 and MEK-2, and no other inhibitors, 
implying that ERK is specific kinase for phosphorylation of HSP70 via EGF signaling (Fig. 
1b). To investigate whether ERK directly phosphorylates HSP70, I performed in vitro kinase 
assay using purified ERK proteins and confirmed ERK-mediated increase of HSP70’s 
phosphorylation in dose-dependent manner (Fig. 1c), suggesting that ERK is direct kinase for 
phosphorylation of HSP70. The phosphorylation on serine residues of HSP70 was also 
observed by overexpression of ERK (Fig. 1d). 




EGF signaling, because binding between substrate and kinase is essential for phosphorylation. 
When the cells were treated with EGF, endogenous and exogenous binding of ERK to HSP70 
was induced (Fig. 1e and f, respectively), suggesting that EGF-dependent phosphorylation of 
HSP70 is mediated by ERK. Direct interaction of the two proteins was further confirmed by 
in vitro pull-down assay (Fig. 1g). I also checked whether EGF signal-mediated activation of 
ERK is required for binding of the two proteins. Upon treatment with U0126, binding of 
ERK to HSP70 declined, suggesting the significance of ERK activity for binding to HSP70 
(Fig. 1h). Taken together, ERK was revealed as the specific kinase responsible for EGF 
signal-dependent phosphorylation of HSP70.  
 
Serine at positions 385 and 400 of HSP70are phosphorylated by EGF stimuli 
Next, the phosphorylation sites of HSP70 were determined. Strep-HSP70-expressing 293T 
cells were treated with or without EGF, and the precipitated Strep-HSP70 was subjected to 
LC-MS analysis for identifying the phosphorylated residues of HSP70 (Fig. 2a). Two other 
peptides containing the phosphorylated serine residu  at positions 385 and 400 were 
identified by mass spectrometry (Fig. 2b). On the structure of HSP70, serine 385 and 400 are 
located in the linker and N-terminus of substrate binding domain (SBD), respectively (Fig. 
2c). To validate whether the residues identified via mass spectrometry were the actual 
phosphorylation sites, I generated the alanine substit tion mutants, S385A, S400A and 
S385A/S400A. 293T cells expressing each of these mutants were stimulated by treatment 
with EGF and the phosphorylation of HSP70 was examined by immunoblotting. S385A- or 
S400A-expressing cells showed mildly induced phosphrylation upon EGF treatment, 




mutant, S385A/S400A, implying that serine 385 and 400 were the real EGF signal-dependent 
phosphorylation sites (Fig. 2d). Next, I further confirmed that these two other residues are 
phosphorylated by ERK. Ectopic expression of ERK phosphorylates HSP70 wild type (WT) 
upon treatment with EGF but not HSP70 double alanine mutant, S385A/S400A (Fig. 2e). 
Altogether serine residues at positions 385 and 400 of HSP70 are phosphorylated by ERK. 
 
HSP70 phosphorylation enhances the protein folding 
To elucidate the significance of phosphorylation in the cell proliferation, I firstly examined 
the canonical function, folding activity, of HSP70. From the re-folding assay using the 
purified HSP70 wild type (WT) and double phospho-mimic mutant, S385D/S400D,proteins, I 
observed that S385D/S400D mutant shows around 1.5 times higher folding activity compared 
to WT (Fig. 3a). Next the aggregated proteins due to improper folding were explored by 
monitoring the in-soluble fraction of cell lysates. Each of Strep-HSP70 WT, S385A/S400A 
and S385D/S400D was introduced into the cells and the amounts of soluble and in-soluble 
fractions from total cell lysates were monitored. When Strep-HSP70 was expressed, the level 
of soluble protein fraction was increased but in-soluble protein fraction was decreased (Fig. 
3b, left). But S385A/S400A- and S385D/S400D-expressing cells showed significant increase 
in in-soluble and soluble protein fractions, respectiv ly (Fig. 3b, middle and right, 
respectively). These results suggested that phosphorylati n of HSP70 enhances its folding 
activity, resulting in productive folding of client proteins. The ubiquitination of whole 
proteins was also monitored in cellular condition which is ectopically expressed by each of 
HSP70 WT or mutant. The cells were treated with proteasome inhibitor and ubiquitination 




amounts of ubiquitination (Fig. 3c, second lane). However, cells expressing HSP70 
containing S385A/S400A and S385D/S400D exhibited higher and lower amounts of 
ubiquitination, respectively (Fig. 3c, third and fourth lane, respectively). These findings 
indicated the significance of HSP70 phosphorylation on its folding activity. I further explored 
the level of well-known client proteins, Akt and CDK4, under different condition of HSP70 
phosphorylation. Expression of double phospho-mimic utant, S385D/S400D, of HSP70 led 
to increase in the levels of its client proteins but not S385A/S400A as expected (Fig. 3d). 
Taken together, the results suggest that phosphorylation enhances the folding activity of 
HSP70, resulting in better quality control and proper folding of client proteins. 
 
Conformational change of HSP70 via phosphorylation 
To unveil how the phosphorylation enhances the folding activity of HSP70, I first 
investigated the binding affinity of HSP70 wild type (WT) or double phospho-mimic mutant 
protein, S385D/S400D, for NRLLLTG, well-known substrate peptide22. From the enzyme-
linked immunosorbent assay (ELISA) the binding affinities of the two proteins to NRLLLTG 
were calculated, and double phospho-mimic HSP70 exhibited about 1.5 times higher affinity 
than WT (Fig. 4a). Similar result was also observed in in vitro pull-down assay using 
NRLLLTG peptide and HSP70 proteins (Fig. 4b). 
HSP70 has distinctly different un-extended and extended conformations, and the 
flexible linker region of the extended form is more exposed than the un-extended from, 
resulting in stronger binding affinity of the extended form to the substrate7. Moreover, 
addition of ATP leads transformation of extended conformation to the un-extended23. Since 




activity than WT, I hypothesized that the phosphorylated HSP70 shows the extended 
conformation harboring more exposed linker and the conformational change from the 
extended form to the un-extended is inhibited via phosphorylation, even after the addition of 
ATP (Fig. 4c). To prove this hypothesis, I conducted the limited digestion assay using 
proteinase K because the exposed linker region is easy to cut by proteinase15. As shown in 
Fig. 4d, as expected, HSP70 WT was protected from digestion of proteinase K by addition of 
ATP; however, ATP-dependent protection failed in case of the double phospho-mimic HSP70, 
suggesting that the phosphorylated HSP70 has the expos d linker region and conformation 
like ADP-bound form. However, there is a lack of understanding about exact conformation of 
the phosphorylated HSP70, and to further validate th  issue, I constructed two other 
fragmented subunits, LgBiT and SmBiT, of nanoluciferase tagged at N- and C-terminal of 
HSP70, respectively; this system emits a luciferase signal if the distance between these two 
fragments is diminished (Fig. 4e). Luciferase signal from HSP70 WT declined upon exposure 
to EGF signal in a time-dependent manner, but not the double phospho-mimic HSP70, 
suggesting that EGF signal-mediated phosphorylation induces conformational change from 
the un-extended form to extended form (Fig. 4f). Thus, it was concluded that the 
phosphorylation on serine residues at 385 and 400 locations of HSP70 induces and enhances 
the formation of the extended conformation, resulting in stronger binding affinity of HSP70 
to its substrate. 
To understand how each phosphorylation residues contribute to the extended 
conformation of HSP70, I analyzed the structure of HSP70 by determining the interaction of 
the linker and SBD containing S385D and S400D, respectively (See Fig. 2c). Through the 




(Fig. 4g and h, respectively). On the contrary, SBD containing S400D also failed to bind with 
linker (Fig. 4i). These results indicated that each of corresponding domain containing S385D 
or S400D fails to bind with its adjacent interacting domain, implying that phosphorylation of 
HSP70 leads to its extended conformation. 
 
Augmentation of cell proliferation via phosphorylation of HSP70 
To investigate whether the enhanced folding activity of HSP70 via its phosphorylation leads 
the enhanced cell proliferation, I examined the viability of 293T cells ectopically expressing 
either HSP70 wild type (WT), S385A/S400A or S385D/S400D. First, I found that 
S385A/S400A and S385D/S400D show lower and higher cell viability than those expressing 
HSP70 WT, respectively (Fig. 5a). Second, I also performed anchorage-independent colony 
forming assay, which revealed similar result as cell viability assay, including significant 
enhancement of colony formation in cells expressing S385D/S400D (Fig. 5b). Third, using 
cytotoxicity assay, I found that the double phospho-mimic HSP70-expressing cells were 
protected from HSP70 inhibitor-mediated cell death. When the cells expressing HSP70 WT 
were treated withVER155008 (VER), which inhibits HSP70 activity by interacting with ATP-
binding pocket in NBD, cell death was enhanced owing to the inhibition of HSP70 activity 
(Fig. 5c, grey). Similarly, S385A/S400A-expressing cells were more vulnerable to VER-
mediated cell death than those expressing WT (Fig. 5c, blue); however, VER could not 
induce cell death in S385D/S400D-expressing cells (Fig. 5c, red), indicating that induction of 
the extended conformation of HSP70 via phosphorylation might protect the cells from VER-




that phosphorylation-mediated regulation of HSP70 activity is more prominent than ATP-
mediated regulation. 
To further validate the pathological implication of HSP70 phosphorylation on cancer 
cells, I analyzed the basic phosphorylation of HSP70 in the absence of EGF signal in normal 
and cancerous lung cells harboring the mutation in EGFR or K-Ras, which is a well-studied 
activator of ERK24. Phosphorylated HSP70 was observed in tested cancer cells, but not in 
normal cells, indicating that cancer cells showing enhanced proliferation exhibit proper 
folding of the translated peptides due to phosphorylated HSP70 besides the other folding 
machinery (Fig. 5d, 1stlane on left). Interestingly, it was also observed that phosphorylation of 
HSP70 was positively correlated with ERK activity, suggesting that ERK, as a kinase, 
mediates phosphorylation of HSP70 (Fig. 5d, right). These results suggest that the activity of 
ERK is a critical determinant of HSP70 phosphorylation and the promoted protein synthesis 
is dependent on the activity of HSP70. 
Taken together, I propose the schematic model for the regulation of the folding 
activity of HSP70 via phosphorylation (Fig. 6). In presence of EGF signal, activated ERK 
phosphorylates the serine residues at position 385 in the linker region and at position 400 in 
the SBD of HSP70. Phosphorylated HSP70 represents the extended conformation of HSP70, 
resulting in the enhanced HSP70 folding activity and cell proliferation. Through the process 







Figure 1. EGF-dependent phosphorylation of HSP70 via ERK. 
 
Figure 1. a, Determination of phosphorylated residues of HSP70 by EGF stimuli. 293T cells 




streptavidin-Sepharose beads. Precipitates were subj cted to SDS-PAGE and immunoblotting 
using indicated antibodies. p-ERK and actin were used as positive controls for EGF signaling 
and loading control, respectively. b, Identification of kinase responsible for phosphorylation 
of HSP70. Strep-HSP70-expressing 293T cells were pre-incubated with indicated inhibitors 
and treated with EGF. Phosphorylation was detected as above. c, Determination of HSP70 
phosphorylation in vitro. Indicated combinations of ATP, HSP70 and ERK were us d for in 
vitro phosphorylation assay. The experiments were independently repeated three times with 
error bars denoting S.D. d, 293T cells containing Strep-HSP70 and GFP-ERK were treated 
with EGF and subjected to immuno-precipitation as above. e, EGF-dependent endogenous 
binding between HSP70 and ERK. H460 cells were treated with or without EGF and 
subjected to immunoprecipitation with antibody against HSP70. Co-precipitation of ERK 
with HSP70 was observed using antibody against ERK. f, 293T cells were transfected with 
Strep-HSP70 and GFP-ERK and treated with EGF. The cells were subjected to 
immunoprecipitation. g, In vitro binding between HSP70 and ERK. Purified GST-HSP70 
were mixed with lysates expressing GFP-ERK and preci itated with glutathione-Sepharose 
beads. Co-precipitated ERK with HSP70 was detected by immunoblotting using anti-GFP 
antibody. GST proteins were observed by coomassie staining. h, 293T cells containing GFP-
ERK and Strep-HSP70 were treated with EGF and U0126 as indicated. The cells were 








Figure 2. Identification of HSP70 phosphorylation residues.  
 
Figure 2. a-b, LC-MS analysis for identification of phosphorylated residues of HSP70 a, 
Strategy for identification of HSP70 phosphorylation sites via LC-MS analysis. b, Mass 




400 (bottom). The identified peptide sequence including the phosphorylated residue was 
presented above its spectrum. Phosphorylated serine is colored as red. c, Cartoon showing 
HSP70 domain arrangement. NBD and SBD indicate nucleotide-binding domain and 
substrate-binding domain, respectively. Serine residues at positions 385 and 400 were located 
in linker and SBD regions, respectively. d, Indicated mutants-expressing 293T cells were 
either or not treated with EGF, and phosphorylation was determined by immunoblotting using 
specific antibodies. e, Strep-HSP70 and GFP-ERK were introduced into 293T cells as 





















Figure 3. a, Re-folding activity of phosphorylated HSP70. Purified HSP70 wild type (WT) 
and double phospho-mimic proteins, S385D/S400D, were subjected to refolding assay. The 
experiments were independently repeated three times with error bars denoting S.D. b, 
Determination of soluble and in-soluble protein fractions following phosphorylation of 
HSP70. Strep-HSP70 wild type (WT), S385A/S400A and S385D/S400D mutants were 
expressed in 293T cells. Soluble and in-soluble protein fractions from whole cell lysates were 
separated and subjected to SDS-PAGE and immunoblotting using anti-Strep antibody. Actin 
was used as a loading control. c, Determination of ubiquitinated proteins via phosphorylation 
of HSP70. Same cells as above were treated with MG-132. The amounts of ubiquitinated 
proteins were determined by immunoblotting using specific antibody against ubiquitin (Ub). 
Quantitated degree of ubiquitination was shown as abar graph in right. d, Indicated HSP70s 
were introduced into 293T cells and the endogenous levels of Akt and CDK4 were evaluated 

















Figure 4. a, Enzyme-linked immunosorbent assay (ELISA) for monitoring interaction 
between HSP70 and NRLLLTG peptide. Binding affinity of NRLLLTG peptide to HSP70 
wild type (WT) or double phospho-mimic, S385D/S400D, proteins were evaluated by ELISA. 
The experiments were independently repeated three times with error bars denoting S.D. b, In 
vitro pull-down assay showing the binding difference of NRLLLTG to HSP70 WT and 
S385D/S400D proteins. Biotin-NRLLLTG or biotin was mixed with two proteins and pulled-
down by streptavidin-Sepharose beads. The precipitates separated by SDS-PAGE were 
subjected to coomassie staining. c, Cartoon showing two different conformations of HSP70. 
d, Limited digestion assay to confirm the conformation f HSP70. HSP70 WT or 
S385D/S400D was pre-incubated with ATP and mixed with varying concentrations of 
proteinase K. Digested proteins were separated and detected by SDS-PAGE and coomassie 
staining, respectively. M denotes the size marker. The number on the left of gel image 
denotes molecular weight (kDa). e-f, Determination of conformational change of HSP70 via 
nanoluciferase assay. e, Schematic diagram of nanoluciferase assay to check the EGF-
dependent change in HSP70 conformation. LgBiT and SmBiT of nanoluciferase were tagged 
to N- and C-terminal of HSP70 WT and S385D/S400D. In presence of EGF signal, two 
distant fragments lead to the decline of luciferase signal. f, The cells expressing each type of 
HSP70 were treated with EGF for varying times and luciferase signal was determined. 
Luciferase signals relative to un-treated sample were shown as bar graph. The experiments 
were independently repeated three times with error bars denoting S.D. g-i, Lysates expressing 
GFP-tagged S385D mutant of HSP70-linker and the purified GST-HSP70-NBD (g) or -SBD 
(h) proteins were subjected to in vitro pull-down assay. Purified HSP70-SBD protein 
including S400D mutation was mixed with lysates expr ssing GFP-tagged HSP70-linker for 









Figure 5. a-c, Determination of cellular function of phosphorylated HSP70. a, HSP70 wild 
type (WT), S385A/S400A and S385D/S400D mutants were int oduced into 293T cells. The 
cells were subjected to MTT assay to examine cell viability. b, Same cells were subjected to 
anchorage-independent colony forming assay. The number of colonies was counted and 
shown as a bar graph. Image on the right denotes the settled colony. c, Same cells were 
treated with different concentration of VER155008 (VER) and subjected to cytotoxicity assay. 
All the experiments were independently repeated three times with error bars denoting S.D. 
(*P<0.05, **P<0.01) d, Cell line analysis showing the varying status of HSP70 
phosphorylation. WI-26, WI-38, H1650, HCC827, A549 and H460 cells were subjected to 
immunoprecipitation to examine the phosphorylation of HSP70 (left). Mutations in EGFR 














Figure 6. Schematic representation for phosphorylation of HSP70 via ERK and its 
cellular function. 
 
 Schematic model for conformational change of HSP70 via phosphorylation of its serine 
residues at positions 385 and 400. In presence of EGF signal, serine residues at positions 385 
and 400 of HSP70 were phosphorylated by ERK. Phosphorylation enhances the extended 













Cancer cells are characterized by rapid cell growth and division compared to normal cells and 
rapid growth and division requires accurate and rapid protein synthesis25. Among the many 
process of protein synthesis, accurate protein folding is very critical to maintain the exact 
structure of proteins, determining its function3. Heat shock proteins (HSPs) are a family of 
chaperones that takes charge of the proper folding of translated peptides1. Among HSPs, 
HSP70 is a well-studied and a promising target for cancer therapy4. However, the level of 
HSP70 does not correlate with the amounts of the productive folded proteins in cancer cells, 
and thus, protein folding efficiency has been studied17. This has raised a question whether 
HSP70 is a real cancer target and many studies tried to solve this problem. Here, I firstly 
report that the phosphorylation of linker region of HSP70 via ERK enhances the protein 
folding activity, resulting in rapid proliferation of cancer cells. It was determined that the 
serine 385 and 400 residues are phosphorylated by ERK upon EGF signaling and the 
phosphorylated HSP70 shows enhanced folding activity, enhancing the cellular protein 
folding. I also determined the mode of action for the increased folding activity via 
phosphorylation. Phosphorylation of serine residues at positions 385 and 400 in linker and N-
terminus of SBD, respectively, leads to the induction of the extended conformation of HSP70, 
resulting in a strong binding affinity between substrate and HSP70.   
HSP70 contains of two domains, NBD and SBD, divided by a flexible linker region6. 
Upon ATP hydrolysis, HSP70 exists in two distinct, un-extended and extended, 




dynamic conformational change via exposed flexible linker region has been studied14; 
however, there is no factor that affects the dynamics of linker region. Our discovery regarding 
the phosphorylation of serine 385 residue on linker region of HSP70 could be the answer for 
dynamics via linker region. Phosphorylated serine 385 residue on linker region failed to bind 
with NBD and SBD of HSP70. This result suggests that phosphorylation on linker of HSP70 
enforces its exposure and enhances the dynamics to the extended conformation. In addition, I 
identified the serine 400 residue as another phosphorylation site. Serine 400 is structurally 
near SBDα, lid domain, in the N-terminus of SBD. Our results show that the phosphorylation 
on serine 400 of SBD leads to decrease of its binding with linker region. This result suggests 
the possibility that lid firmly covers the substrate-binding pocket of SBD, resulting in strong 
binding affinity of substrate to SBD because the lid is closed in the extended form of 
HSP7023. Thus, phosphorylation sites, serine 385 and 400, could be an efficient target to 
regulate the structural dynamics of HSP70. 
Recently, a few research groups have reported the phosphorylation sites in NBD and 
SBD of HSP70 and revealed the significance of phosprylation in pathological condition26. 
In cancer cells, hyperactive kinases phosphorylate HSP70, resulting in two hot spots for 
phosphorylation, one in NBD and another in SBD27. Increased HSP70 phosphorylation by 
hyperactive kinases promotes cancer progression via regulation of protein stabilization, cell 
cycle, and response to cancer drug10,12,13. However, there is no report about phosphorylation 
in the linker of HSP70, because the importance of linker for dynamics and function of HSP70 
is not thoroughly studied. Here, I firstly reported the phosphorylation site, serine 385, in 
linker region and its significance in process of folding and cellular effect. Although I need to 




functional analysis of phosphorylation of serine 385 residue of HSP70 in this report is crucial 
for understanding the regulation of folding activity of HSP70 via phosphorylation in linker 
region. 
ERK is a well-studied kinase activated by growth signal24. Activated ERK mainly 
regulates the transcription factors associated with protein translation and translational 
machinery molecules facilitating cell proliferation a d survival28. In this study I unveiled that 
the activated ERK via EGF signal controls the conformation of HSP70 via phosphorylation, 
resulting in its augmented folding activity. Thus, the novel function of ERK, direct regulation 
of productive folding, is revealed from this study. 
HSPs have been considered as an attractive therapeutic target to cure cancer since a 
long time; however, targeting HSPs accompanies a significant challenge from redundancy. In 
fact, the reason many trials targeting HSPs have fail d was generation of toxicity to normal 
cells in addition to cancer5. In this regard, phosphorylated HSP70 could be a vry attractive 
target for curing the cancer cells. Phosphorylation of HSP70 could be considered as a 
pathological, not physiological, phenomenon, and thus, therapeutic agents used to target the 
phosphorylated HSP70 could be specific to cancer cells, not normal cells. Resistance and 
addiction to the therapeutic agents targeting the pos horylated HSP70 could not be found 
either because post translational modification, especially phosphorylation, is transient. Since 
phosphorylation of HSP70 is also tightly dependent o  the activation of ERK and many 
studies have reported enhanced activation of ERK in cancercells29, many patients could be 
benefitted by this approach. Thus, targeting the phos orylated HSP70 for curing cancer 







Cell culture and materials 293T and WI-26 cells were cultured in DMEM media 
supplemented with 10% FBS and 1% penicillin/streptomycin in 5% CO2 at 37°C, 
respectively.WI-38, A549, H460, HCC827and H1650 were cultivated in RPMI with same as 
above. All the used cells and GFP-tagged ERK were gift d from biobank of Biocon. GFP-
HSP70 (#15215) was purchased from addgene and sub-cloned into EcoRI/XhoI sites of 
pEXPR-IBA105. Each of HSP70 domains was cloned intoEc RI/XhoI sites ofpEGFP-C3, 
pEGFP-N1 and pGEX4T-1. Point mutagenesis of HSP70 was performed with Quik-ChangeII 
(Promega), following the manufacturer’s instruction. EGF was purchased from Peprotech. 
MG-132 and antibody against p-Ser were purchased from Sigma. Antibodies for p-Thr, p-Tyr, 
p-ERK and ERK were purchased from Cell signaling Technology and others from Santa Cruz 
Biotechnology. StrepMAB-classic-HRP, for detecting Strep, was purchased from iba. 
 
Identification of phosphorylation site Strep-HSP70-expressing 293T cells were incubated 
with or without EGF for 10 minutes and purified with strep-tactin column. The purified 
HSP70 was analyzed by SDS-PAGE and subjected to in-gel digestion with Trypsin/Lys-C 
(Promega). For identification of phospho peptides, the analysis of peptide mixture was 
performed using LTQ-OrbitrapVelos (Thermo Fisher Scientific) connected to Easy-nano LC 
II system (Thermo Fisher Scientific) incorporating an autosampler. Acquired data from data-
dependent mode to simultaneously record full-scan mss and collision-induced dissociation 




phosphorylation on phosphopeptides, CID spectra were s arched for the peptides containing 
modification, p-Ser, p-Thr and p-Tyr, by a combinaton of database searches and by plotting 
neutral loss chromatograms to show characteristic loss of a phosphate group. Proteome 
Discoverer (version 1.3, ThermoScienific, Waltham, MA USA) and Scaffold program 
(version 4.8.4, Proteome Software Inc., Portland, OR) were used to validate MS/MS-based 
peptide and protein identifications and to process the quantitative analysis. Precursor mass 
tolerance and fragment mass tolerance were set to 25 ppm and 0.8 Da. 
 
In vitro kinase assay Phosphorylation of HSP70 by active ERK1 protein (Enzo life sciences) 
was monitored using universal kinase activity kit (R&D systems). 0.15 mM of purified 
HSP70 and 1 mM of ATP were mixed with 2 to 50 ng/ml of ERK1 in phosphatase buffer 
containing 250 mM HEPES, 1.5 M NaCl, 100mM MgCl2 and 100 mM CaCl2. Coupling 
phosphatase, CD39L2, was added for generation of inorga ic phosphate from ADP resulted 
from kinase reaction. After incubation on room temprature for 10 minutes, malachite green 
reagent was added for termination of reaction. Amount of phosphorylated HSP70 was 
determined by measuring OD at 600 nm in microplate reader and the experiments were 
repeated three times independently. 
 
Re-folding assay Glow-Substrate peptide was un-folded by heating at 40°C for 7 minutes 
and subjected to re-folding assay using HSP70/HSP40 Glow-Fold Protein Refolding kit 
(BoostonBiochem), following the manufacturer’s instruc ion. For quantification of the re-




Promega) at various reaction times (10, 20, 30, 40, 50 and 60 minutes). The experiments were 
independently repeated three times. 
 
Limited digestion assay For limited digestion assay using the purified HSP70 wild type and 
S385D/S400D mutants were incubated with proteinase K according to the previously 
reportedmethod15,16. 10 μg of HSP70 protein was pre-incubated with 200 μM ATP at room 
temperature and proteinase K was added in dose-depen nt manner. Enzyme reaction was 
done in room temperature and stopped by adding the SDS sample buffer and boiling at 
100 °C for 10 minutes before SDS-PAGE with coomassie taining. 
 
Luciferase assay Each of HSP70 wild type orS385D/S400D mutants was cloned into 
pBiT1.1-N[TK/LgBiT], and SmBiT fragment of pBiT2.1-N[TK/SmBiT] was cloned at the C-
terminus of HSP70 for generating the construct thatLgBiT and SmBiT of nanoluciferase 
were tagged to N- and C-terminal of HSP70. 293T cells ctopically expressed with each 
plasmid were treated with EGF (50 μg/ml) for 30, 60, 90 and 120 minutes. After incubation 
for indicated time, the luciferase activity was determined by the nanoluciferase assay system, 
following the manufacturer’s protocol (Promega). The experiments were independently 
repeated three times. 
 
Enzyme-linked immunosorbent assay 150 ng of purified NRLLLTG peptide was diluted in 
0.05 M sodium carbonate buffer (pH 9.6) and coated on a flat-bottom 96-well plate (Thermo). 




including 1% BSA solution were done. Each well was washed with PBST, and HSP70 wild 
type or S385D/S400D mutant protein was added in dose- ependent manner. After washing 
with PBST, primary antibody against HSP70 and its secondary antibody were incubated 
serially. 3,3',5,5’-tetramethylbenzidine (TMB) solution (Thermo) detected bound HSP70 
using 1N H2SO4for developing and stopping the reaction. The absorbance was measured at 
450 nm with 620 nm reference and all the experiments were repeated 3 times. 
 
In vitro pull-down assay Purified GST-tagged proteins were mixed with cell lysates 
containing GFP-tagged proteins in 50 mM Tris-HCl (pH 7.4) binding buffer containing 100 
mM NaCl, 0.5% Triton X-100, 10% glycerol, 1 mM EDTA, and protease inhibitor 
(Calbiochem) at 4°C. After 12 hours, GST proteins were precipitated by glutathione 
Sepharose beads and washed with binding buffer three times, and co-precipitates with GST 
proteins were separated by SDS-PAGE. The amounts of GFP- and GST-tagged proteins were 
detected by immunoblotting using anti-GFP antibody and coomassie staining, respectively. 
 
Immunoprecipitation The cells were lysed with 50 mM Tris-HCl (pH 7.4) lysis buffer 
containing 100 mM NaCl, 0.5% Triton X-100, 0.1% SDS, 10% glycerol, 1 mM EDTA, and 
protease inhibitor (Calbiochem). Whole cell lysates were mixed with interesting antibody 
pre-incubated with agarose G for 12 hours. After incubation, precipitates with agarose G were 
washed with cold lysis buffer excluding 0.1% SDS three times. Strep-tagged HSP70 were 
precipitated with strep-tactin column (IBA), following the manufacturer’s instruction. Co-





Soluble and in-soluble protein fractionation The 293T cells dose-dependently transfected 
with each of Strep-HSP70 wild type, S385A/S400A and S385D/S400D mutant were lysed 
with 50 mM Tris-HCl (pH 7.4) buffer containing 0.5% Triton X-100 and protease inhibitor 
(Calbiochem). After lysis for 30 minutes at 4 °C, whole cell lysates were separated into 
supernatant and pellet fraction by centrifugation at 13,200 rpm for 15 minutes at 4 °C. The 
pellet fraction was dissolved with the lysis buffer adding 1% SDS. The amounts of proteins in 
each fraction was measured by spectrophotometer using Bradford (Biorad) solution. The 
experiments were independently repeated three times. 
 
Anchorage-independent colony forming assay Each of Strep-HSP70 wild type, 
S385A/S400A and S385D/S400D mutant was introduced into 293T cells. The cells were 
subjected to anchorage-independent colony formation assay using cell transformation assay 
kit (CELL BIOLABS, INC.), following the manufacture’s instruction. After cell culture for 1 
week, soft agar was solubilized and the colonies were stained by MTT solution (Sigma) and 
counted. The experiments were independently repeated thr e times. 
 
Cell viability assay 293T cells (1x 104) ectopically expressing each of Strep-HSP70 wild 
type, S385A/S400A and S385D/S400D mutant were cultured in single well of 96 well plate 
for 24 hours. The cells in the each well were treated with 10 μl of MTT solution (5 mg/ml, 
Sigma) and incubated for 1 hour at 37 °C. After discard the culture media, the precipitated 




at 560 nm using a micro plate reader (Sunrise, TECAN). The experiments were 
independently repeated three times. 
 
Cell toxicity assay The 293T cells expressing Strep-HSP70 wild, S385A/S400A or 
S385D/S400D were seeded in 96 well white plate and cultured for overnight. Several doses 
of VER155008 (2.5, 5, 10 and 20 μM) were treated for 6 hours and dead cells were evaluated 
with CytoTox-Glo kit (Promega). After adding the mixture of AAF-Glo substrate and buffer, 
cells were incubated in 37 °C for 10 minutes and luminescence signal from dead cells was 
measured by luciferase reader (GloMax, Promega). The experiments were independently 
repeated for three times. 
 
Quantification and statistical analysis Statistical tests were performed with Prism 
(GraphPad). A value of P<0.05 was considered statistically significant. All error bars 
represent standard deviation (s.d.). For quantitative data, statistical parameters are reported in 
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Heat shock protein 70의 결합에 의한 AIMP2-DX2 안정화 기전과 
 결합 억제제를 이용한 항암 효능 연구 
 
 
정상세포에 비해 비정상적으로 증식하는 암세포는 세포의 성장과 사멸을 조절하
기 위해 oncoprotein의 증가를 요한다. 이 때문에 oncoprotein의 안정성을 도모하는 
Heat Shock Protein (HSP)은 암을 억제하기 위한 주요한 표적이 된다. 그러므로 
HSP을 직접적 또는 간접적으로 조절하는 방법은 암 치료에 이용될 수 있다. 
 암유발인자인 Aminoacyl-tRNA synthetase interacting multifunctional protein2-
deleted exon2(AIMP2-DX2)는 여러 가지 암세포에서 증가되어 있음에도 불구하고 
그의 세포 내 단백질조절기전이 알려져 있지 않다. 이 연구는 HSP70이 AIMP2-
DX2의 레벨을 조절하는 중요인자임을 보고한다. Mass spectrometry를 기반으로 한 
interactome 분석을 통해 HSP70이 AIMP2-DX2의 interactor임을 확인하였고, X-ray 
crystallography와 NMR으로 두 단백질의 결합구조를 분석하였다. HSP70의 
substrate-binding domain은 AIMP2-DX2의 N-terminal flexible 부분과 GST-domain 부
분을 인지하고 결합하여, Siah1에 의한 ubiquitination을 억제함으로서 AIMP2-DX2 
단백질을 안정화시킨다. AIMP2-DX2로 인해 유도되는 세포형질전환과 암의 진행
은 HSP70에 의해 촉진되었다. 또한 다양한 폐암 세포들과 폐암환자조직분석은 두 
단백질의 정적상관관계를 보여준다. 더 나아가 AIMP2-DX2:HSP70 결합을 저해하




는 암 진행을 촉진하는 AIMP2-DX2:HSP70 결합을 증명하며, 그의 억제가 암 치
료제로 이용될 수 있는 가능성을 제시한다. 
 빠르게 증식하는 암세포는 생존을 위해서 HSP70에 의한 단백질 folding 의 
효율적 작동을 필요로 한다. 이로 인해, HSP70은 암 진행을 저해할 수 있는 
주요표적으로 연구된다. 하지만, 아직까지 HSP70의 활성을 조절할 수 있는 
인자나 그에 대한 기전연구가 미비하다. 본 연구는 HSP70의 인산화가 folding 
activity 에 미치는 영향을 규명한다. HSP70 linker의 385 그리고 substrate-binding 
domain 의 400번 serine residue가 EGF 신호에 의해 인산화된다는 것이 mass 
spectrometry와 mutant study를 통해 확인되었다. EGF 신호 아래에서 직접적으로 
HSP70을 인산화시키는 kinase는 ERK 임을 확인하였다. 두 serine잔기의 인산화는 
HSP70의 구조변화를 야기하고, 결과적으로 펼쳐진 구조를 갖게 된다. 변화된 
구조는 HSP70과 client 단백질의 결합을 증진시켜 HSP70에 의한 folding 을 
증가시키고, 이로 인한 세포의 증식을 가속화시킨다. EGF 신호의 중요인자인 
EGFR 과 KRAS 의 변이를 갖는 다양한 세포에서 높은 활성을 갖는 ERK 에 의한 
HSP70인산화가 증가되어 있음이 확인되었다. 본 연구는 ERK 에 의한 HSP70 
인산화가 HSP70의 canonical function 을 조절하고 세포증식의 변화에 영향을 
미친다는 것을 보여준다. 
 위 두 가지 연구결과를 통하여 HSP70을 조절할 수 있는 서로 다른 두 
가지 방법을 보여준다. HSP70과 specific substrate의 결합을 억제하는 방법과 
HSP70의 활성에 영향을 미치는 인산화를 조절하는 방법을 제시한다. 두 가지 
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